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Abstract 
Amyloid-beta oligomers (AβOs) induce neurological dysfunction in part through 
the cellular prion protein (PrPC) resulting in deregulation of Ca2+ homeostasis in 
Alzheimer’s disease (AD). Stress inducible phosphoprotein 1 (STIP1), a cochaperone of 
Hsp70 and Hsp90, protects neurons from AβO-induced cell death. As well, STIP1 
interacts with the Ca2+ sensor S100A1, which is an important biomarker upregulated in 
AD and regulates STIP1 and other cochaperone association with Hsp70 and Hsp90. 
While the molecular details of STIP1-Hsp complexes are well studied, little information 
is available concerning alternate STIP1 binding partners. Here, we investigated the 
structural details of STIP1 binding to PrPC and S100A1.  
We showed that residues located in a short region of PrP (90-110) mediate AβO 
binding and refined the main interaction to residues 91-100. We identified that STIP1 
binds to PrP through multiple domains (DP1, TPR1 and TPR2A) and that the interactions 
with TPR1 and TPR2A effectively block AβO binding to PrPC and cell death. The DP1 
domain interacted with the flexible N-terminal (residues 23-95), while TPR1 and TPR2A 
interacts with the C-terminal (residues 90-231) of PrP.  NMR spectroscopy revealed that 
the TPR domains interact with PrP competitively through distinct regions, with the 
TPR2A binding site overlapping with Hsp90. Our data suggest PrP, STIP1 and Hsp90 
may form a ternary complex, which may influence AβO toxicity in cells.   
In contrast to PrP complex formation, S100A1 binding to STIP1 is Ca2+ 
dependent and mediated through the TPR (TPR1, TPR2A and TPR2B) domains of 
STIP1. Each TPR binds asymmetrically to a single S100A1 dimer resulting in a 
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stoichiometry of three S100A1 dimers binding a single STIP1 molecule. S100A1 bound 
each TPR through a common interface spanning α-helix IV; however, with different 
binding affinities. Our findings provide novel structural insights regarding STIP1 
complexes with PrPC and S100A1. 
 
Keywords 
Alzheimer’s disease, neurotoxicity, cochaperone, neuronal cell death, S100A1, stress-
inducible phosphoprotein 1, prion protein, nuclear magnetic resonance spectroscopy, 
neurodegeneration, amyloid-β 
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1.1 Protein aggregation and neurological disorders  
Protein aggregation into amorphous bodies is a common mechanism shared by most 
neurodegenerative diseases. Proteins that coalesce into abnormal intracellular or 
extracellular fibrils and inclusion bodies within specific brain regions generally 
characterize disease pathology [1]. Huntington’s disease, prion diseases, amyotrophic 
lateral sclerosis (ALS), Parkinson’s and Alzheimer’s disease (AD) all involve formation 
of abnormally folded proteins that accumulate as insoluble aggregates extracellularly or 
in the cytoplasm. 
Alzheimer’s disease is predominately a late-onset neurodegenerative disorder and the 
most prevalent form of dementia. The disease typically is diagnosed in patients 65 and 
older and results in a progressive loss of memory and executive function, confusion, 
agitation and behavioral abnormalities. AD afflicts approximately 24 million people 
worldwide and the rate of incidence is expected to increase exponentially with an aging 
population [2, 3]. Alzheimer’s disease cases are segregated into 2 subtypes based on age 
of onset. Early-onset AD (EOAD) patients range from 30-65 years and form the minority 
of cases (1-6%), while late-onset AD (LOAD) cases are characterized in individuals 65 
years old and over [3]. AD is a multi-factorial disorder with multiple genetic and 
environmental factors affecting disease predisposition. 
The neuropathology of AD is defined by the accumulation of two insoluble filaments; 
intraneuronal neurofibrillary tangles (NFT) and extracellular amyloid plaques [4, 5]. 
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NFTs are composed of the hyperphosphorylated microtubule associated protein tau while 
amyloid plaques are the result of accumulation and self-aggregation of the amyloid-beta 
(Aβ) peptide into larger macromolecular assemblies. Tau and Aβ act separately and 
interdependently to promote synaptic dysfunction and neuronal cell death [6]. 
The functional link between Aβ and tau was first described in in vivo mouse models 
of tau and Aβ deposition. Injection of preformed Aβ fibrils into P301L mutant tau 
transgenic mice, which develop a non-Alzheimer’s tauopathy, frontotemporal dementia 
with parkinsonism linked to chromosome 17, resulted in a five-fold increase in NFT 
accumulation at the site of injection [7]. Additionally, crosses of tauP301L mice with the 
familial EOAD causative mutation (K670N/M671L) in the amyloid precursor protein 
(APP) resulted in accelerated tau deposition with no change in plaque burden compared 
to either parental mouse line alone [8]. These studies suggest Aβ can exacerbate NFT 
formation without affecting amyloid deposition.  
Numerous protein kinases have been implicated to functionally connect Aβ to tau 
hyperphosphorylation at the molecular level. GSK3β, ERK1/2 and Cdk5-p25 have been 
described to phosphorylate tau at Ser/Thr-Pro sites and are stimulated by Aβ treatment 
[9-12]. Interestingly, recent studies suggest the non-receptor tyrosine kinase, Fyn, 
hyperphosphorylates tau in response to activation by Aβ oligomer (AβO) through 
molecular complexes that include the cellular prion protein (PrPC), metabotropic 
glutamate 5 (mGluR5) and N-methyl-D-aspartate (NMDA) receptors [12-15]. Thus, 
current models postulate Aβ accumulation upstream of tau hyperphosphorylation in AD. 
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1.2 Amyloid precursor protein (APP) processing 
The amyloid precursor protein (APP) is a single-pass transmembrane protein with a 
large ectodomain. Eight isoforms are generated by alternative splicing though the 695 
amino acid isoform is predominately expressed in the central nervous system (CNS) [16]. 
The major proteolytic APP pathway involves sequential cleavage of APP by α and γ 
secretase complexes generating non-amyloidogenic fragments sAPPα and intracellular 
fragment that are associated with synaptic plasticity and neuronal protection (Figure 1.1) 
[17, 18]. Alternatively, sequential proteolytic processing by the β and γ secretases results 
in a heterogeneous population of peptide variants (Aβ43, Aβ42, Aβ40, Aβ38 and Aβ37) 
with various propensities to self-associate into larger amyloidogenic species [19, 20]. The 
predominant peptide products are Aβ40 and Aβ42, with the former being the major 
species in the normal state. In AD the ratio of Aβ42: Aβ40 increases with Aβ42 
becoming the main proteolytic product [21]. Aβ42 possesses enhanced amyloidogenic 
properties and the shift towards Aβ42 production is characteristic of AD. Thus, AD 
results increased APP processing by the amyloidogenic pathway and failure to clear the 













Figure 1.1. Sequential cleavage of the amyloid precurosr protein (APP).  
APP is processed by two mechanisms. In the non-amyloidgenic pathway, APP is initially 
cleaved by α-secretase followed by γ-secretase resulting in production of a soluble 
ectodomain (APPsα) and an intracellular fragment. Amyloidgenic processing involves 
sequential cleavage by β-secretase followed by γ-secretase resulting in the formation of 
Aβ peptide and a soluble APPsβ fragment. Both processes generate intracellular C-






In the amyloidogenic pathway, the transmembrane aspartic protease BACE1 
functions as the β-secretase, initially cleaving the ectodomain of APP generating a 
membrane anchored β- C-terminal fragment (β-CTF) (Figure 1.1). The γ-secretase is a 
multiprotein complex composed of presenilin 1 (PS1) or presenilin 2 (PS2), nicastrin 
(Nct), Aph-1 and Pen-2, which plays a functional role in the proteolytic processing of 
transmembrane proteins [22]. Mutations in PS1, PS2 and APP have been linked as 
causative mutations of autosomal dominant familial AD [3]. The γ-secretase cleaves the 
intramembranous fragment at one of several locations in the intramembrane helix 
generating the various length Aβ peptides. Aβ40 and Aβ42 are the most commonly 
generated, with the latter increased in EOAD associated mutations. Aβ42 has been 
classically viewed as the more toxic species and demonstrates a greater propensity for 
self-association into oligomers, protofibrils, fibrils and ultimately, the characteristic 
amyloid plaques seen in AD. 
1.3 Amyloid-β oligomers and toxicity 
While amyloid plaques are a hallmark of AD neuropathology, studies have been 
unable to demonstrate a relationship between amyloid plaque load and neuronal death, 
synaptotoxicity or disease severity [23]. Neuronal death is observed in regions far 
removed from plaques and cases have been reported of non-demented individuals with 
high plaque burden [24-26]. These studies suggest an alternative species is primarily 
responsible for synaptic dysfunction in AD. The identification of small diffusible Aβ 
oligomers (AβO) provides a rationale for these discrepancies. AβO are prefibrillar 
intermediates which are potent neurotoxins [27]. Robust correlations are observed 
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between soluble AβO concentrations and disease severity, thus the field considers soluble 
AβOs as the predominant neurotoxin in AD [28, 29].  
Aβ polymerization follows a complex and multifaceted pathway generating a range 
of buffer-soluble oligomers (i.e. dimers, trimers, tetramers, dodecamers and high 
molecular weight oligomers) during fibril formation [20]. Atomic force and electron 
microscopies revealed them to be 10-15 nm spherical shaped structures [30]. AβO are 
potent neurotoxins thought to trigger synaptic dysfunction, neuronal cell death and 
dementia [30]. The current paradigm in AD suggests these soluble oligomeric species are 
the primary pathological unit and not the amyloid plaques, which characterize the 
disease. 
Toxicity is thought to depend on size and aggregation state; however, due to the 
diverse oligomeric and structural heterogeneity of AβOs, the toxic species and their 
relative potency is poorly defined [20]. The diversity of synthetic and natural AβOs has 
complicated the interpretation and reproducibility of studies [31]. SDS-stable dimers and 
trimers are secreted in culture and are found in human diseased brain extracts, which 
inhibit long-term potentiation (LTP) [32]. LTP is an electrophysiological mechanism 
underlying learning and memory formation and is compromised in AD. Larger species 
(nonamers and dodacamers) have also been observed to correlate with memory deficits in 
an APP transgenic mouse model [33]. As well, larger assemblies over 100 kDa have been 




Synthetic preparations of AβOs have been employed to elucidate disease 
mechanisms in vitro and in an attempt to better standardize AβO preparations [35]. 
Synthetic AβO, also referred to as Aβ-derived diffusible ligands (ADDLs) mimic AβO 
induced deficiencies including robust binding to neurons, inhibition of LTP, 
synaptotoxicity and neuronal cell death [27]. Antibodies generated against synthetic 
ADDLs derived oligomers cross-reacted with AD brain tissue, demonstrating synthetic 
ADDL conformations are generated in vivo and are relevant in studies of AD [36]. 
Multiple molecular mechanisms have been implicated to contribute to AβO 
toxicity. AβO association with the plasma membrane results in increased intracellular 
calcium concentrations and excitotoxicity in neurons [37]. AβO have been found to 
compromise the integrity of the plasma cell membrane, disrupting intracellular calcium 
homeostasis [38, 39]. AβOs insert themselves into lipid bilayers leading to pore 
formation or lipid bilayer defects resulting in ion deregulation [40]. Rapid increases in 
intracellular Ca2+ promote further deficits, such as increases in radical formation and 
oxidative stress [41]. Elevation of intracellular Ca2+ concentrations by compromising its 
cellular membrane integrity may contribute to the potent neurotoxicity of AβOs and 
neurodegeneration in AD. 
Alternatively, binding of AβOs to the cell surface through endogenous cellular 
receptors may result in aberrant signaling, synaptic dysfunction and neuronal cell death. 
Indeed, a number of amyloid-protein interactions have been described between native 
neuronal receptors or co-receptors/scaffold proteins resulting in detrimental effects [42]. 
These include α7 nicotinic acetylcholine receptor (α7nAChR), receptor for advance 
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glycation end products (RAGE), ephrin type B receptor 2 and paired immunoglobulin –
like receptor B [43]. Receptors in glutamatergic transmission have garnered tremendous 
interest in AβO toxicity. Glutamate is a portent neurotransmitter essential in memory 
formation and synaptic plasticity [44]. In particular, the N-methyl-D-aspartate (NMDA) 
receptor and metabotropic glutamate receptors (mGluR) have been demonstrated to be 
susceptible to deregulation by AβO resulting in Ca2+ influx and synaptotoxicity [45, 46]. 
AβO were shown to depolarize neurons, disrupt glutamatergic transmission, inhibit LTP, 
promote LTD and excitotoxicity [47, 48].  
AβO have been demonstrated to activate NMDA receptors through the NR2B subunit 
and inhibit LTP [49]. Interestingly, the cellular prion protein (PrPC) has been identified as 
a coreceptor for NMDA, mGluR5 receptors and AβOs [12, 13]. AβO binding to PrPC 
induces NMDA and mGluR5 activation resulting in Fyn kinase activation, thus 
potentially coupling AβO toxicity to hyperphosphorylation of tau protein in AD [12, 13]. 
1.4 Cellular prion protein (PrPC) 
The cellular prion protein (PrPC) is the pathological unit of several progressive and 
fatal neurodegenerative diseases termed prion diseases. These include Creutzfeldt-Jakob 
disease (CJD), kuru, fatal familial insomnia (FFI) and Gertzmann-Straussler-Scheinker 
syndrome (GSS) in humans, scrapie in goats and sheep, chronic wasting disease (CWD) 
in deer and elk and bovine spongiform encephalopathy (BSE) in cattle [50]. Conversion 
of the normal PrPC to an alternate β-sheet and protease resistant conformer (PrPSc) is 
thought to be behind the etiology of prion diseases [51, 52]. PrPSc conversion can occur 
sporadically or be promoted by mutations within the PrPC gene [53]. PrPSc particles are 
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transmissible, promoting conversion of endogenous PrPC to the pathogenic conformer 
and initiating progressive neurodegeneration in the host. 
PrPC knockout mice are resistant to prion infection while, for the most part, 
maintaining normal neurological function [54, 55]. Subtle neurological phenotypes have 
been identified including slight deficiencies in synaptic transmission, LTP, circadian 
rhythms, spatial learning and increased susceptibility to seizures [56-58]. As well, lower 
levels of anxiety and increases in locomotor activity have been observed in particular 
backgrounds of PrP-null mice [59]. Ablation of PrPC was also noted to result in a chronic 
demyelinating polyneuropathy [60].   
PrPC is a carboxy-terminal glycophosphatidylinositol (GPI) anchored protein located 
on the outer leaflet of the cellular plasma membrane (Figure 1.2) [61]. A 22 amino acid 
N-terminal signaling peptide targets the nascent protein to the lumen of the endoplasmic 
reticulum, where the signaling peptide is cleaved and the protein undergoes post-
translational modification [62]. The mature protein is trafficked to the cellular membrane 
through the Golgi apparatus and undergoes endocytosis and cycling from the cell 
membrane and intracellular compartment. Pulse-chase experiments indicate the half-life 
of PrPC is about 1.5-2 hrs, demonstrating the protein undergoes rapid recycling [63]. 
Internalization of PrPC is dependant on the N-terminal region of PrPC and the initial basic 
cluster ‘KKRPK’ [64, 65].  
Mature PrPC contains flexible disordered N-terminal spanning residues 23-124 and a 
structurally conserved globular C-terminal (Figure 1.2) [66, 67]. The disordered N-
terminal encodes two regions of high conservation termed the octapeptide region (OR) 
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and a region rich in hydrophobic amino acid content spanning 22-90 and 111-134, 
respectively. The OR encodes four to five octameric repeats possessing a high affinity for 











Figure 1.2. Structure of cellular prion protein (PrPC).  
PrPC is composed of a disordered N-terminal and a C-terminal globular domain rich in α-
helical content. The protein is tethered to the extracellular face of the plasma membrane 









The globular C-terminal presents a highly α-helical fold composed of three helices 
(residues 145-151, 173-188 and 200-229) and a short a β-sheet formed by residues 128-
131 and 161-164 [66, 67]. A single disulfide bond connects α-helices 2 and 3, 
significantly contributing to PrPC stability [69]. PrPC is subject to glycosylation at N181 
and N197 positions in human PrPC (N180 and N196 in mouse) and has been isolated in 
the unglycosylated, mono- or di-glycosylated forms [70]. Different glycosylation states 
have been reported to be differentially distributed through the central nervous system and 
other tissues [71-73]. High-resolution structural studies by solution nuclear magnetic 
resonance (NMR) spectroscopy and X-ray crystallography have revealed a high degree of 
inter-species structural homology [67, 74, 75].  
The prion protein is ubiquitously expressed in adult tissues and highly enriched 
within cholesterol-rich lipid rafts of neuronal postsynaptic membranes in the central 
nervous system (CNS) [76]. As well, high expression has been noted in elements of the 
immune system, hematopoietic stem cells (HSCs), blood and lymphoid organs [77].  
PrPC is a scaffold protein that modulates cellular signaling at the cellular membrane 
through protein-protein interactions with various cellular ligands [76]. These include a 
diverse set of ligands including laminin, heparin sulfate, casein kinase 2 (CK2) and 14-3-3 
[78-81]. Protein-protein interactions have been mapped throughout the extent of the 
protein; however, large numbers of PrPC binding partners interact through the disordered 
N-terminal region, presumably due to its increased accessibility on the plasma membrane 
compared to its C-terminal GPI-anchored globular domain.  
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PrPC has been identified as a high affinity receptor for soluble AβO, in an 
unbiased screen of a cDNA library expressed in COS-7 cells [82]. PrPC associates with 
AβOs with sub-nanomolar affinity through residues 23-27 and 95-110 of the N-terminal 
of PrPC [82-84].  Immuno-staining of neuronal cultures following AβO results in 
characteristic punctate staining on the neuronal surface [82]. AβO staining can be 
significantly reduced by pretreatment with anti-PrPC antibodies or RNA silencing of 
PrPC; however these strategies do not eliminate AβO binding suggesting AβO retains the 
capacity to bind neuronal cells through alternate mechanisms such as other identified 
binding partners [82, 85].  
Association of PrPC or the disordered N-terminal containing these binding sites 
inhibited the oligomerization and fibrillization of AβO in vitro [86, 87]. Alternatively, 
PrPC disassembled mature fibrils into smaller AβO species, potentially stimulating 
formation of neurotoxic species [88]. Thus, binding of AβO to PrPC may influence the 
kinetics of Aβ oligomerization and the toxicity of the generated Aβ species; however, the 
implications of these observation on neurotoxicity are currently unknown. 
PrPC is required for cell death in vitro, epileptiform discharges, synapse loss, 
serotonin axon degeneration and cognitive and memory deficits associated with AβO [82, 
89-91]. Association of AβO or AD brain extracts resulted in the inhibition of LTP in CA1 
hippocampal slices in a PrPC dependent manner [82]. 
PrPC directly interacts with mGluR5 [92, 93]. Synthetic AβO or AβO isolated 
from AD disease brain resulted in PrPC-dependent activation of Fyn kinase [12]. AβO-
PrPC engagement resulted in increased intracellular Ca2+ levels, eEF2 phosphorylation, 
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reduction in global transcription, and dendritic spine loss. PrPC- AβO complex formation 
also disrupts NMDA receptor activity resulting in a biphasic transient increase in Ca2+ 
and NMDA receptor surface expression [13].   
Initially, binding of AβO to PrPC resulted in Fyn activation, NR2B subunit 
phosphorylation, and increased NMDA receptor trafficking to the cell surface. This 
increase is coupled to increased intracellular Ca2+ resulting in excitoxicity followed by 
dendritic spine loss. Following 60 minutes of AβO treatment, NMDA receptor surface 
expression is reduced, desensitizing neuronal cells and resulting in the attenuation of the 
Ca2+ currents.  
The cytotoxic stresses induced by PrPC- AβO complexes have made the interaction an 
appealing target for therapeutic intervention. Disruption of AβO-PrPC complexes using 
monoclonal antibodies directed against the PrPC -AβO binding site (residues 95-110) or 
α-helix 1 demonstrated the greatest efficacy, either by directly blocking the binding site 
or occluding it by steric hindrance [82, 84, 94]. This inhibition translated to inhibition of 
AβO-induced deficits. Thus, modulation of PrPC- AβO complex may be of therapeutic 
value in AD. Interestingly, the PrPC ligand, stress-inducible phosphoprotein 1 (STIP1) 
inhibits AβO binding and toxicity implicating the pathway as an endogenous protective 






1.5 Hsp70 and Hsp90 chaperones 
Proper protein folding in the cell is facilitated through a large and diverse class of 
chaperones termed heat shock proteins (Hsp). Hsp90 is one of the best conserved Hsps 
and accounts for 1-2% of total protein in the cell [96]. Hsp90 activity is regulated through 
interactions with a large network of cochaperones to fold a wide range of client proteins 
that include a number of oncogenic protein kinases and steroid receptors. Initially, client 
proteins are recruited by Hsp40 and Hsp70 and are transferred to Hsp90 by stress-
inducible phosphoprotein 1 (STIP1) [97]. Finally, an additional co-chaperone p23 is 
recruited and ATP hydrolysis results in structural rearrangements in Hsp90 that promote 
client maturation and dissociation of the complex [97]. Recent studies suggest Hsp90 has 
an important role in neurodegeneration. Hsp90 stabilizes toxic aggregates such as Aβ and 
phosphorylated tau [98]. Pharmacological inhibition of Hsp90 results in Hsp70 and 
Hsp40 upregulation, which is thought to channel aberrant folded species for degradation 
[98]. 
1.6 Stress-inducible phosphoprotein 1 (STIP1) 
Stress-inducible phosphoprotein 1 (STIP1) is a cellular cochaperone that coordinates 
Hsp70 and Hsp90 activity during client protein folding [99, 100]. STIP1 expression is 
upregulated during cellular stress in yeast [101]. STIP1 is a modular protein composed of 
three tetratricopeptide repeat domains (TPR1, TPR2A and TPR2B) and two domains rich 
in aspartate and proline residues (DP1 and DP2) (Figure 1.3). Tetratricopeptide repeat 
domains are composed of repeating units of 34 amino acid degenerate sequences that 
form two anti-parallel α-helices joined by a short flexible linker [102]. Multiple TPR 
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motifs are arranged in tandem forming an amphipathic groove, which serves as the 




























Figure 1.3. Structural schematic of stress-inducible phosphoprotein 1 (STIP1). 
Individual domain boundaries are highlighted with their corresponding structures 
depicted below: TPR1 (PDB: 1ELW), DP1 (residues 1138-190 (2LLV), TPR2A-TPR2B 










The TPR domains of STIP1 bind Hsp70 and Hsp90 to facilitate client protein 
folding. The amphipathic groove of each TPR domain binds the C-terminal ‘EEVD’ 
motifs of Hsp70 and Hsp90, anchoring them to the protein [103]. Specificity is achieved 
through amino acid contacts directly N-terminal of the ‘EEVD’ motifs of each Hsp. This 
interaction is predominately mediated through conserved electrostatic interactions 
forming a two-carboxylate clamp with the Asp residue in each Hsp70 and Hsp90 peptide. 
While the C-terminal Hsp interactions are critical for TPR and Hsp90 binding, additional 
contacts are made with the middle domain of Hsp90 [104, 105]. 
Binding of Hsp90 by STIP1 results in non-competitive inhibition of its ATPase 
activity through interaction with TPR2A-TPR2B fragment and stabilizes an open 
conformation in Hsp90; however, the human homologue appears to be an approximately 
10-fold less potent inhibitor [106, 107]. Hsp engagement is facilitated through sequential 
interactions with the individual TPR domains of STIP1 [108]. The function of the DP 
domains (DP1 and DP2) is less clear. Currently, no protein ligands have been identified 
for the DP domains of STIP1. Recently, the solution NMR structures of the yeast DP1 
and DP2 domains were solved revealing a novel α-helical protein fold encoding six and 
five α-helices, respectively [104]. DP1 contains an additional α-helix that is believed to 
stabilize the arrangement of secondary structural elements and occupies a slightly 
positive groove. This groove is accessible in DP2 and may serve as a potential binding 
site for as of yet unidentified ligands. The minimal fragment of STIP1 that supports client 
activation is composed of TPR2A-TPR2B-DP2 C-terminal of STIP1 [104, 109]. As well, 
the C. elegans STIP1 homologue only encodes this fragment which suggest the TPR1-
DP1 module may be dispensable for client activation in vivo [110]. 
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Interestingly, constructs lacking the DP2 domain did not support glucocorticoid 
receptor activation in yeast cells [104]. X-ray crystallographic structures of the TPR2A-
TPR2B domain revealed the linker between these domains is quite rigid. This results in 
the TPR domains adopting an S-shaped form with their hydrophobic clefts responsible 
for binding the C-terminal Hsp residues oriented in opposite directions [104]. 
Complementary NMR spectroscopy experiments revealed additional inter-domain 
contacts are formed between the C-terminal helix of TPR2B, the linker connecting 
TPR2B to the DP2 domain and α-helices 1 and 2 of the DP2 domain. These additional 
contacts form a rigid C-terminus composed of TPR2A-TPR2B-DP2. These results 
indicate DP2 contributes to the quaternary structure of STIP1 and rationalizes its 
importance in STIP1 function. 
STIP1 possesses two Hsp70 binding sites located in TPR1 and TPR2B; however, 
it binds to Hsp70 in a 1:1 stoichiometry [103, 108]. The current model for STIP1 function 
in Hsp70 and Hsp90 coordination speculates that in the absence of Hsp90, the TPR2B 
domain represents the high-affinity binding site for Hsp70. Hsp90 binding induces a 
more ‘open’ conformation between TPR1-DP1 fragment and the functional C-terminal 
TPR2A-TPR2B-DP2 domains. Hsp90 binding to TPR2A reduces accessibility of Hsp70 
binding to TPR2B, thus the TPR1 domain becomes the predominant binding site for 
Hsp70 in the ternary complex [108]. Binding of Hsp90 has been observed to affect the 
dynamics of STIP1, reorienting the TPR1-DP1 module into close proximity to TPR2B, 
presumably facilitating transfer of Hsp70. Thus, the length of the linker bridging TPR1-
DP1 to TPR2A-TPR2B-DP2 impacts STIP1 function in client refolding. Deletion of the 
linker results in decreased formation of ternary complexes of STIP1-Hsp70-Hsp90 and 
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decreased protein client activation in vivo [108]. Interestingly, this linker is 
approximately 30 residues shorter in higher order eukaryotes. Thus, differences in 
dynamics of STIP1-Hsp70-Hsp90 ternary complexes may exist in higher order 
eukaryotes affecting client protein activation [108].  
STIP1 is subject to posttranslational modification, which regulates its 
cochaperone activity [109]. Five different phosphorylation sites have been identified in 
human STIP1 homologue corresponding to S16, S189, T198, Y354 and S481. 
Phosphomimetic mutations resulted in decreased glucocorticoid receptor activation in 
vivo and Hsp70 binding affinities indicating phosphorylation regulates STIP1’s co-
chaperone function [109]. Interestingly, Y354E phosphomimetic variant located in the 
loop joining TPR2A-TPR2B, appeared to disrupt the rigid linker joining the two domains 
and promotes a more dynamic flexibility and leads to a loss of function [109]. 
Additionally, STIP1 is subject to SUMOylation by PIAS1 whose binding results in its 
nuclear accumulation [111]. 
Hsp70 and Hsp90 overexpression is a common phenotype of human cancers and 
correlates with a poor prognosis [112]. Pharmacological inhibition of the Hsp machinery 
has become a popular target in cancer treatment [113]. Recent studies have explored 
inhibition of STIP1 cochaperone function as an alternate strategy in destabilizing Hsp90 
oncogenic ligand folding [114, 115]. Studies have demonstrated that STIP1 promotes 
proliferation and migration in glioblastoma and pancreatic cancer cell lines [116, 117]. 
Down-regulation of STIP1 by RNAi resulted in decreased pancreatic cell line 
invasiveness and down-regulation of numerous oncogenic Hsp90 client proteins [116]. 
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Inhibition of Hsp90 interaction with the TPR2A domain of STIP1 using a novel hybrid 
TPR peptide has demonstrated selective cancer-cell cytotoxicity [118]. 
Selective inhibition of the Hsp machinery has also garnered interest in 
neurodegenerative diseases owing to their roles in regulating proper protein folding. 
Inhibition of Hsp90 results in upregulation of Hsp70 and Hsp40 through transcriptional 
activation of the transcription factor heat-shock factor 1 (HSF-1). Hsp40 and Hsp70 
overexpression are thought to promote protein disaggregation and degradation [119]. 
Hsp90 is believed to stabilize aberrantly folded proteins, thus inhibition of the chaperone 
and co-chaperone activity at particular nodes may be of therapeutic value in protein 
aggregation disorders [120]. 
1.7 STIP1 as a signaling molecule 
In addition to STIP1’s well-documented role as an Hsp cochaperone, STIP1 also 
functions as a neurotrophic and neuroprotective signaling molecule through PrPC [121-
124]. STIP1 is actively secreted by a non-canonical pathway through extracellular 
vesicles (EVs) [125]. Upon cellular stress, such as irradiation or ischemia, astrocyte 
STIP1 secretion is enhanced promoting cell survival through PrPC-dependent pathways 
[121, 122]. The hydrophobic core of PrPC (residues 113-128) has been determined to 
engage in complex formation with the TPR2A (residues 230-245) of STIP1. Complex 
formation promotes perturbation of PrP α-helix  (143-153) of the globular C-terminal of 
PrPC and compaction of STIP1 structure in PrPC-STIP1 complex [126]. These structural 
remodeling events may recruit additional protein interactions and is consistent with PrPC 
function as a scaffold protein-modulating cell signaling events. 
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PrPC- STIP1 engagement results in an increase in intracellular Ca2+ concentration 
through the α7 nicotinic acetylcholine receptor (α7nAChR) (Figure 1.4) [127]. Signaling 
induces neuroprotection and neuroproliferative signaling through PKA and ERK1/2 
pathways, with the latter requiring internalization of PrPC [128]. α7nAChR expression is 
altered in AD models and the receptor itself has been identified as an AβO receptor 
[129]. Inhibitors against AβO binding to α7nAChR show beneficial effects in AD 






Figure 1.4. STIP1 signaling pathway through PrPC at the cellular membrane. 
STIP1 binding to the N-terminal flexible tail of PrPC results in intracellular Ca2+ influx 
from the outside environment through the α7nAChR. The resulting cascade leads to PKA 








In addition, STIP1 signaling through PrPC enhances neuronal protein synthesis 
through PI3K-Akt-mTOR activation and phosphorylation of eIF4E-binding proteins (4E-
BPs), which release eIF4E initiation factor, promoting translation initiation [131]. 
Regulation of protein synthesis by extracellular signaling molecules is involved in critical 
pathways in neuronal development and synaptic plasticity in the nervous system [132]. 
Stimulation of neuronal protein synthesis is corrupted by scrapie prion (PrPSc) infection, 
thus loss-of function of this pathway may contribute to the neurodegeneration seen in 
prion diseases [131].  
Deletion of STIP1 in mouse models is embryonic lethal by E 10.5 and embryos 
presented malformed neural tube and limb buds due to increased levels of apoptotic cell 
death [122]. Maternal extraembryonic STIP1 protein, possibly transferred, from placental 
disruption is sufficient for initial blastocyst (E 3.5) implantation and survival; however, is 
not present in E10.5 embryos. Embryonic fibroblasts from STIP1 deficient embryos 
present increased DNA damage marker γ-H2AX [122]. Enhanced cellular stress induces 
STIP1 translocation and accumulation of STIP1 in the nucleus [133]. Nuclear localization 
is regulated by phosphorylation at S189 and T198 located in the linker joining TPR1-DP1 
to the C-terminal of STIP1 and adjacent to the functional NLS (residues 222-239) [134]. 
As well, interaction of STIP1 with the E3 SUMO ligase PIAS1 results in STIP1 
accumulation after genotoxic stress following irradiation [111]. Thus, STIP1 nuclear 
accumulation is influenced by cellular stress and by protein posttranslational 
modifications and ligand interactions. 
A growing body of evidence has revealed alternate functions of STIP1 unrelated to its 
regulation of Hsp70/Hsp90 activity. Importantly, extracellular STIP1 is a potent 
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neuroprotective signaling molecule through PrPC [95, 124, 127, 128]. STIP1 can directly 
inhibit AβO binding to PrPC in vitro by physically occluding the AβO site and 
neuroprotective signal transmission through α7nAChR, which translated to rescue of 
AβO induced toxicity [95]. A thorough molecular understanding of the PrPC-STIP1 
interaction may provide insight into cellular mechanisms involved in the early stages of 
disease and potential therapeutic strategies in AD. 
1.8 S100A1 
Disruption of calcium homeostasis is implicated in numerous and diverse human 
diseases including heart disease and several neurological disorders [135]. Calcium 
signaling mechanisms are tissue and cell specific, temporarily regulated and undergoing 
continuous remodeling. Diverse signaling cascades promote mobilization of intracellular 
or extracellular stores through numerous Ca2+ channels, pumps and exchangers [136]. 
Deregulation of calcium signaling resulting in disruption of membrane conductance has 
long been associated with AD pathology, preceding deposition of Aβ plaque deposition 
and inflammation that define AD pathology [137-139]. Intracellular AβO have been 
demonstrated to induce Ca2+ flux by directly permeabilizing the membrane or through 
activation receptor signaling complexes and Ca2+ channels [39, 49, 140]. Fluctuations in 
Ca2+ influence synaptic plasticity and processes such LTP and long term depression 
(LTD) and thus AβO can disrupt learning and memory in AD. 
Ca2+ also functions as an important cofactor in a large set of calcium sensor proteins, 
modifying protein-protein interactions and influencing downstream events. The S100 –
family of proteins is a well-studied family of calcium sensor proteins encompassing 
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approximately 20 member proteins [141]. S100-family function as modulators in calcium 
signaling. Expression of these proteins is cell type and tissue specific and their 
differential expression has been implicated in a diverse range of diseases, including 
psoriasis, rheumatoid arthritis, cardiomyopathy, multiple sclerosis, Down’s Syndrome, 
Alzheimer’s disease and several forms of cancer [142-145]. Thus, many S100 proteins 
serve as diagnostic biomarkers in disease. 
S100 proteins are homo or hetero dimeric proteins of the EF-hand superfamily. Each 
subunit is composed of two helix-loop-helix EF-hand motifs (residues 19-32 and 62-73 in 
S100A1), which coordinate four calcium ions [146-148] (Figure 1.5). In the apo-state α-
helices III lie nearly perpendicular to α-helices IV, burying a large hydrophobic pocket 
that serves as the binding site for many S100 ligands [148]. Upon calcium binding, α-
helix III of each subunit undergoes a large conformational reorientation of approximately 
100° exposing the hydrophobic face of α-helices IV, which along with residues of α-
helices III and the interconnecting hinge region, serve as the predominant ligand binding 













Figure 1.5. Ribbon diagram of apo-S100A1 (left) (PDB: 1K2H) and Ca2+-bound 
S100A1 (right) (PDB: 1ZFS). 
Ca2+ induces a conformational change, which reorients α-helices III of each protomer 










S100A1 was one of the first family members discovered and originally isolated 
from bovine brain tissue [150]. The protein is abundantly expressed in heart, skeletal 
muscle and brain tissues [151]. S100A1 expression has been implicated in multiple and 
diverse human diseases including specific types of cancer, heart failure and neurological 
diseases, importantly AD. S100A1 is found in the hippocampus, cerebral cortex and 
amygdala [152]. The protein is found both in intracellular compartments as well as in the 
extracellular space where it interacts with several cell surface receptors [151, 153]. 
S100A1 has been found to regulate APP processing, tau phosphorylation and Aβ 
oligomer induced neuronal cell death. Knockout of S100A1 in AD mouse models 
resulted in decreased hippocampal inflammation, and decreased Aβ amyloid plaque 
burden [144, 154]. As well, numerous S100A1 ligands have been implicated in AD such 
as the receptor for advanced glycation end products (RAGE) and ryanodine receptors 
[154] [155].  
Recent studies have implicated S100A1’s role in the regulation of co-chaperone 
interactions with Hsp70/Hsp90 chaperone machinery [156]. These co-chaperones include 
protein phosphatase 5 (PP5), FK506-binding protein (FKBP52), cyclophilin 40 (Cyp40) 
and STIP1 [156] [157]. S100A1 inhibited their association through binding each ligand’s 
respective TPR domains, which are commonly used by co-chaperones to interface with 
the conserved C-terminal ‘EEVD’ motifs found in Hsp70 and Hsp90. Therefore, S100A1 




1.9 Scope of thesis 
STIP1 is a multifaceted protein molecule that functions as a cellular cochaperone, 
regulating Hsp70 and Hsp90 activity and client maturation. STIP1 binding to S100A1 
protein has been suggested to influence its interactions with Hsps. Additionally, 
extracellular STIP1 acts as a potent neuroprotective and neurotrophic signaling molecule 
through PrPC. Therefore, molecular understanding of STIP1 ligand interactions has 
implications in numerous cellular diseases including cancer and neurodegeneration.  
In order to ascertain the structural details of STIP1 ligand complexes, extensive NMR 
characterization of STIP1 was undertaken. 1H-15N HSQC spectra revealed the protein 
was too large to acquire adequate information on STIP1 complexes, thus the individual 
TPR (TPR1, TPR2A and TPR2B) and DP (DP1 and DP2) domains were cloned and 
studied individually (chapter 2). NMR backbone assignments were completed and 
confirmed to agree with the currently available literature. These NMR assignments 
provide the foundation for the study of STIP1-ligand complexes. As well, the impact of a 
wide range of conditions on the stability of the previously identified ligand binding 
domains of STIP1, the TPR domains, was assessed. 
The modular structure of STIP1 and structural similarity of the TPR domains lead us 
to explore the potential of alternate binding sites of PrPC than previously reported. We 
discovered that in addition to the TPR2A domain, the TPR1 and DP1 domains bound 
PrP. DP1 bound the flexible N-terminal of PrPC, while the TPR domains bound 
competitively to PrP (90-231). In addition, the AβO binding site on PrP was refined to 
residues 90-110. The TPR1 and TPR2A domains could inhibit AβO to PrPC in vitro and 
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in primary neuronal mouse cultures. Importantly, this inhibition translated to reduced 
neuronal cell death. 
Finally, the molecular details of the recently identified and poorly understood STIP1-
S100A1 complex was investigated. Both proteins are secreted and S100A1 is a marker 
for neuronal stress and injury [125, 142]. S100A1 may regulate STIP1 interactions in the 
extracellular and intracellular environment. The stoichiometry of binding was determined 
to be 3 S100A1 dimers per STIP1 molecule. Each TPR domain of STIP1 participated in 
binding to each S100A1 dimer; however, with significantly different binding affinities 
determined by isothermal titration calorimetry (ITC). NMR was used to define the 
binding interfaces for S100A1 and individual TPR domains. The binding interface for 
each TPR domain on S100A1 was determined to encompass a large hydrophobic groove 
spanning α-helix III of S100A1 and was shared amongst each TPR domain. These results 
suggested differences in binding were due to the amino acid composition of each TPR. 
Due to spectral broadening, the binding site on each TPR could not be identified with 
great confidence and alternate strategies for obtaining the S100A1 binding site on TPR 
domains are discussed. 
The work presented in this thesis has advanced our understanding of molecular 
complexes of STIP1 involved in AD. The structural details of interaction between STIP1 
and PrP were explored and novel regions were identified to mediate binding and inhibit 
AβO toxicity in neuronal cultures. As well, the molecular details of the poorly 
understood STIP1-S100A1 complex were defined. These results provide structural details 
and provide the foundation for future studies of STIP1 ligand complexes beyond the 
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2 Structural characterization of STIP1 domains 
2.1 Introduction 
Proper folding of nascent peptides by molecular chaperones is a fundamental 
process of life. Heat-shock proteins (Hsp)70 and Hsp90 are evolutionary conserved 
chaperones which mediate folding of key cellular client proteins involved in proliferation, 
differentiation and apoptosis [1, 2] . Hsp90 targets include numerous oncogenic proteins 
implicated in tumor growth and survival including steroid hormone receptors and proto-
oncogenic kinases such as Akt [3], Raf-1 [4] and Her2/neu [5]. Hsp90 over-expression 
correlates with tumor invasiveness and poor prognosis, thus pharmacological inhibition 
of the chaperone response has become an alluring target for therapeutic intervention in 
multiple cancer models [6]. 
Client maturation is facilitated by a number of co-chaperone proteins that regulate 
Hsp70 and Hsp90 activity. Hop/STIP1 (Hsp-organizing protein/stress-induced-
phosphoprotein 1) is a key scaffold protein, which coordinates client transfer from Hsp70 
to Hsp90 in the later stages of client maturation [7, 8]. Initially, client proteins complex 
with Hsp40 and Hsp70 [9, 10]. Hop/STIP1 initiation promotes client transfer from Hsp70 
to Hsp90 by simultaneously binding the two chaperones through distinct tetratricopeptide 
repeat (TPR) domains [11].  
Hop/STIP1 is a modular protein composed of three structurally related TPR 
domains (TPR1, TPR2A and TPR2B) and two aspartate-proline rich regions (DP1 and 
DP2) [12]. TPR domains are composed of multiple degenerate 34 amino acid repeats 
forming anti-parallel helix-turn-helix motifs. These serve as protein-protein interaction 
  
46 
modules in multi-protein complexes [13]. Hsp coordination by TPR domains is 
accomplished through the conserved C-terminal residue ‘EEVD’ motifs of Hsp70 and 
Hsp90. X-ray crystallographic data of human and yeast TPR domain complexes with 
Hsp70 and Hsp90 C-terminal peptides indicate specificity is determined by hydrophobic 
contacts directly N-terminal of the ‘EEVD’ motif [11]; however, additional extensive yet 
poorly understood contacts are formed between STIP1 and Hsps, stabilizing the 
interaction [14]. The TPR1 and TPR2B domains facilitate Hsp70 binding, while TPR2A 
is the primary Hsp90 binding site [15]. During client maturation Hsp70 is initially 
recruited to the TPR1 domain of STIP1. Upon Hsp90 binding, Hsp70 is transferred to the 
TPR2B domain to facilitate client transfer from Hsp70 to Hsp90 [15].   
The functional roles of the DP domains of STIP1 are more enigmatic. The TPR1 
and DP1 domains are dispensable for client protein maturation, with the minimal 
functional fragment comprising of TPR2A-TPR2B-DP2 [14]. Inter-domain contacts have 
been identified between the DP2 and TPR2A-TPR2B domains of yeast STIP1, while the 
DP1 domain is thought to function as a flexible linker facilitating transfer of Hsp70 from 
the TPR1 to the TPR2B domains [15]. 
Studies have demonstrated that STIP1 promotes proliferation and migration in 
glioblastoma and pancreatic cancer cell lines [16, 17]. Down-regulation of STIP1 by 
RNAi resulted in decreased pancreatic cell line invasiveness and down-regulation of 
numerous oncogenic Hsp90 client proteins [17]. Inhibition of Hsp90 interaction with the 
TPR2A domain of STIP1 using a novel hybrid TPR peptide has demonstrated selective 
cancer-cell cytotoxicity [18]. Thus, inhibition of STIP1 binding to Hsp machinery has 
been suggested as an alternative approach in novel cancer therapeutics [19, 20]. 
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Secreted STIP1 also functions as a cell-signaling molecule promoting 
neuritogenesis and neuroprotection in hippocampal neurons through its interaction with 
the cellular prion protein (PrPC) [21-24]. The PrPC binding site of STIP1 has been 
localized to the N-terminal of STIP1, with TPR1, DP1 and TPR2A domains of STIP1 
contributing to complex formation (See Chapter 3). Recently, neuroprotective signaling 
induced by PrPC-STIP1 complex formation rescued primary mouse hippocampal neurons 
suggesting PrPC-STI1 may play a role in the progression of Alzheimer’s disease [25].  
Nuclear magnetic resonance (NMR) spectroscopy has been proven to be a robust 
technique in the study of macromolecular complexes. NMR provides detailed structural 
information on a per residue basis to unambiguously identify regions of macromolecules 
which interact or undergo conformational changes upon complex formation [26]. The 1H-
15N HSQC (Heteronuclear Single Quantum Correlation) spectra contain a single peak 
corresponding to each amino acid in a protein (except proline residues which lack amide 
protons) and serve as a “finger-print” of a protein [26, 27]. Upon, titration of a binding 
ligand, residues involved in complex formation or undergoing a conformational change 
(i.e. change in their chemical environment) demonstrates perturbations in their peak 
resonances and allows to identify the protein-ligand interfaces at the structural level. 
For this approach to be effective, the identity of each peak in the 1H-15N HSQC 
spectra must be correlated to a particular residue in the protein sequence. This requires a 
series of experiments to assign the individual backbone amides to particular peaks in the 
spectra. Backbone resonance assignment of the individual domains of STIP1 domains 
and characterization of the TPR domains will provide the foundation for the study of 
STIP1 protein-protein interactions, as well as provide the structural basis for the 
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screening of selective inhibitors of Hsp complex formation that may prove as effective 
cancer treatments and for future studies involving the STIP1-PrPC signaling complex and 
other ligand interactions.  
2.2 Materials and Methods 
2.2.1 Protein expression and purification 
The expression vectors containing mouse full-length STIP1 and the individual 
domains (TPR1 (residues 1-118), DP1 (residues 119-216), TPR2A (residues 217-352), 
TPR2B (residues 353-480) and DP2 (residues 481-542)) were transformed in E. coli 
BL21 (DE3) pLysS. For backbone amide resonance assignment of each STIP1 domain 
(TPR1, DP1, TPR2A, TPR2B and DP2), uniformly 15N, 13C- labeled protein was over-
expressed by growing E. coli in 1 L M9 media supplemented with 1 g of 15NH4Cl and 3 g 
of 13C-glucose at 37°C to an OD600 of 0.9, at which point protein over-expression was 
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). For all other 
experiments, the protein was grown in M9 minimal media without isotopically labeling 
the protein. Cultures were grown overnight at 22°C and centrifuged pellets were frozen 
for storage. N-terminally His-tagged fusion proteins were purified by affinity 
chromatography using Ni SepharoseTM 6 Fast Flow beads (Amersham Biosciences). The 
N-terminal His-tag was removed by incubation with His-tagged Tobacco Etch Virus 
(TEV) protease overnight at 22 °C and proteins were analyzed by SDS-PAGE. TEV 
protease was removed by an additional Ni2+ affinity chromatography step. Proteins were 
dialyzed into the appropriate buffers for further experimentation as noted. 
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2.2.2 Circular dichroism (CD) Spectropolarimetry 
CD spectra were acquired on a Jasco J-810 spectropolarimeter (Easton, MD). 
Spectra of TPR1 and TPR2A at approximately 0.1 mg/mL concentrations were collected 
in 10 mM sodium acetate, pH 5 or 50 mM sodium phosphate pH 7 or 8 buffers 
supplemented with 1mM DTT at 20°C. Five accumulated scans were used for each 
spectrum. Thermal denaturation was conducted over a temperature range consisting of 
10°C to 95°C. The spectra were deconvoluted using the CDSSTR analysis program from 
the DichroWeb (http://dichroweb.cryst.bbk.ac.uk) online analysis software package using 
the SMP180 (optimized for 190-240 nm) reference set [28, 29]. 
2.2.3 Analytical Ultracentrifugation – Sedimentation Equilibrium 
and Gel Filtration Chromatography 
Analytical ultracentrifugation (AUC) experiments were performed at 20 °C in 50 
mM sodium phosphate, 50 mM NaCl, 1 mM DTT, pH 7.0 on TPR2A (50 µM) using a 
Beckman Optima XL-A Analytical Ultracentrifuge equipped with an An60Ti rotor 
containing six-channel Epon-charcoal centerpieces and 1.2 cm path length. 
(Biomolecular Interactions and Conformations Facility, University of Western Ontario). 
Absorbance measurements were collected at 290 nm in 0.002 cm radial steps and 
averaged over 10 scans. Sedimentation equilibrium measurements were collected at rotor 
speeds of 16 000, 20 000, 24 000 and 28 000 rpm. Data was fit to the following global 




(Equation 1) where C is the concentration of protein at radius x, C0 is the concentration at 
initial radius x0, ω is the angular velocity, vbar is the partial specific volume of the protein, 
ρ is the solvent density, R is the ideal gas constant, T is the absolute temperature, I0 is the 
baseline offset and Mobs is the fit of the molecular weight based on sedimentation data.  
Analytical gel filtration of TPR2A was carried out on a Superdex 75 gel filtration 
column (Amersham Biosciences) in 50 mM sodium phosphate, 50 mM NaCl, 1mM DTT, 
pH 7 at a flow rate of 0.5 mL/min. The elution profile was compared to the following 
globular protein standards of known molecular weight: 67 kDa, 43 kDa, 23 kDa, 13.7 
kDa.  
2.2.4 Backbone amide NMR Resonance Assignments 
STIP1 domains (TPR1, DP1, TPR2A, TPR2B, DP2) were dialyzed into 50 mM 
sodium phosphate buffer, 50 mM NaCl, 1mM DTT at pH 7 and subsequently 
concentrated to ~ 500 µM. NMR samples contained 10 % D2O and 100 µM 2,2-
dimethyl-2-sila-pentane-5-sulfonic acid (DSS) for 1H and 13C chemical shift referencing. 
NMR experiments for backbone resonance assignments of each domain were conducted 
at 25°C on a Varian INOVA 600 MHz spectrometer equipped with either a cryogenic 
probe or a regular triple resonance probe (UWO Biomolecular NMR Facility). Sequential 
assignments were obtained for each domain using the following Biopack experiments: 
TPR1 (HNCACB, CBCA(CO)NH and C(CO)NH), DP1(HNCACB, CBCA(CO)NH and 
C(CO)NH), TPR2A (HNCACB and CBCA(CO)NH), TPR2B (HNCACB and 
CBCA(CO)NH) and DP2 (HNCACB, CBCA(CO)NH). All spectra were processed using 
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NMRPipe  and analyzed using CARA [30]. NMR spectral images were presented using 
NMRViewJ or SPARKY [31-33]. 
Chemical shift assignments have been deposited in the BioMagResBank 
(http://www.bmrb.wisc.edu), under accession numbers 18691 and 18689 for the TPR1 
and TPR2A domains, respectively. 
2.2.5 HSP90 chemical shift mapping 
Binding of the TPR2A domain to the peptide encoding the C-terminal Hsp90 
residues (Ac-MEEVD-NH2) (GenScript Inc. USA) was confirmed by 1H-15N HSQC 
spectra collected in the presence and absence of equimolar concentrations of Hsp90 
peptide (~250 µM). Experiments were collected on a Varian INOVA 600 MHz 
spectrometer equipped with a cryogenic probe (UWO Biomolecular NMR Facility).  
The magnitude of chemical shift perturbations for traceable residues was 
calculated from the combined chemical shift changes in 1H and 15N dimensions (Δω = 
|0.2 * Δ15N| + |Δ1HN|) in ppm. The resultant chemical shift changes were mapped on to 
the crystal structure of TPR2A (PDB: 1ELR) and presented using UCSF Chimera 
Molecular Modeling System [11, 34]. 
2.3 Results 
2.3.1 Structural analysis of STIP1 
The relative large molecular weight of STIP1 (63 kDa) and multi-domain 
assembly raised the question if detailed structural studies by NMR were feasible. Full-
length STIP1 was successfully purified from the soluble fractions in E. coli BL21 
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(pLysS) (Figure 2.1B) TEV incubation led to successful removal of the poly-histidine tag 
and purification of soluble STIP1 of high purity (>95%). 1H-15N NMR HSQC spectra of 
full-length STIP1 contained a small subset of the backbone amide resonances 
(approximately 150 peaks) expected for a protein of this size (543 residues) (Figure 2.1B) 
STIP1 appeared to be of the correct molecular weight when analyzed by SDS-PAGE 
indicating the lack of amide resonances is not the result of protein degradation (Figure 
2.1C). The majority of the resonances which are resolved cluster in a narrow region in the 
HSQC spectrum, spanning ~1 ppm. The narrow spectral width of these resonances 
signifies they likely represent flexible loop-regions or inter-domain linkers of STIP1. The 
absence of signals from the folded functional domains of STIP1 is likely due to its large 
















Figure 2.1. 1H-15N HSQC of full-length STIP1 indicates NMR spectroscopy of full-
length protein is unfeasible due to lack of backbone amide resonances. 
(A) 1H-15N HSQC spectra of full-length STIP1. (B) SDS-PAGE of purified STIP1. (lane 
1) Soluble bacterial lysate of E. coli over-expressing STIP1. (lane 2)  Ni2+ 
chromatography purified 6xHis-tagged STIP1 (5 µg). (lane 3) STIP1 following 
incubation with TEV for 6xHis-tag cleavage and removal (5 µg) or (lane 4) (10 µg). 










2.3.2 Assignment of structural domains of STIP1 
The individual folded functional domains of STIP1 (TPR1, DP1, TPR2A, TPR2B 
and DP2) were isolated to facilitate study of STIP1 ligand interactions at the molecular 
level. The molecular weights of individual STIP1 domains range from ~7-17 kDa (Figure 
2.1A) making them amenable for study by NMR compared to full-length STIP1. 
To the best of our knowledge, no amide backbone assignments are available for 
the mammalian STIP1 domains, thus NMR experiments were conducted to assign the 1H-
15N HSQC spectra of each of the domains. Backbone resonance assignments for 1HN, 15N, 
13Cα and 13Cβ were obtained for the TPR domains (TPR1, TPR2A and TPR2B) of 
STIP1. For the TPR1 domain, 97% of the 1HN and 15N resonances of non-proline 
residues, 94% 13Cα and 87% 13Cβ of all residues were assigned (Figure 2.2A and B). For 
the TPR2A domain, 99% of 1HN and 15N resonances of non-proline residues, 95% 13Cα 
and 96% 13Cβ of all residues were assigned (Figure 2.3A and B). Secondary structure 
propensity scores calculated using the assigned 13Cα and 13Cβ chemical shifts predict 
TPR1 and TPR2A to be composed of seven α-helical regions each separated by an 
interconnecting disordered region with low α-helical propensity (Figure 2.2C and 2.3C) 
[35]. No β-strand character is seen for the assigned residues. The predicted α-helical 
propensity and their arrangement correlates with the x-ray crystal structures solved for 
the human TPR1 and TPR2A domains and their cognate C-terminal Hsp ligands, 
legitimizing the accuracy of the assignment [11]. 
For the TPR2B domain, 94% of the 1HN and 15N resonances of non-proline 
residues, 93% 13Cα and 95% 13Cβ were assigned (Figure 2.4A and B). Currently, no 
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high-resolution structural information is available for mammalian TPR2B. However; SSP 
score predicts 7-α helical structure, which agrees with the TPR1 and TPR2A domains of 
STIP1 and structurally aligns with the available yeast TPR2B structures (PDB: 3UPV) 
solved by NMR (Figure 2.4C) [14].  
The molecular functions of the DP domains of STIP1 remain enigmatic and no 
ligand interactions have been identified to date. However; DP1 and the interconnecting 
linker with TPR2A influences client activation in vivo and the DP2 domain has been 
described as essential in yeast client activation. The solution NMR structure for the yeast 
DP1 and DP2 domains were recently solved and revealed a novel α-helical fold, with the 
α-helices of DP2 arranged to form a groove, which may serve as a binding pocket for as 
of yet unidentified ligands [14]. Thus, we conducted NMR experiments to assign the DP 
domains of mammalian STIP1. For DP2, 98% of 1HN and 15N resonances of non-proline 
residues were assigned, 98% 13Cα and 98% 13Cβ (Figure 2.5A and B). SSP score 
prediction indicated an all α-helical fold with an disordered C-terminal in agreement with 
the solved yeast solution structure (Figure 2.5C) [14]. Five regions of α-helical 
propensity were identified, which align with the solved yeast structure (PDB: 2LLW), 
suggesting the fold is conserved between yeast and mammalian STIP1 [14].  
Unfortunately, due to a large amount of signal degeneracy and poor signal 
strength of the 13Cα and 13Cβ from the HNCACB and CBCA(CO)NH experiments, only 
39% of the DP1 domain could be assigned with low confidence (Figure 2.6A). Further 




Figure 2.2. (A) 1H-15N HSQC spectrum and backbone assignment of 15N/13C labeled TPR1 domain of STIP1. 
(B) Amino acid sequence of TPR1 domain with unassigned residues colored red. The N-terminal glycine is a non-native residue from 





Figure 2.3. (A) 1H-15N HSQC spectrum and backbone assignment of 15N/13C labeled TPR2A domain of STIP1. 
(B) Amino acid sequence of TPR2A domain with unassigned residues colored red. The N-terminal glycine is a non-native residue 
from the TEV protease recognition site. (C) Secondary structure propensity (SSP) scores calculated for TPR2A based on 13Cα/β 




Figure 2.4. (A) 1H-15N HSQC spectrum and backbone assignment of 15N/13C labeled TPR2B domain of STIP1. 
(B) Amino acid sequence of TPR2B domain with unassigned residues colored red. The N-terminal glycine is a non-native residue 
from the TEV protease recognition site. (C) Secondary structure propensity (SSP) scores calculated for TPR2B based on 13Cα/β 




Figure 2.5. (A) 1H-15N HSQC spectrum and backbone assignment of 15N/13C labeled DP2 domain of STIP1. 
(B) Amino acid sequence of DP2 domain with unassigned residues colored red. The N-terminal glycine is a non-native residue from 





Figure 2.6. (A) 1H-15N HSQC spectrum and backbone assignment of 15N/13C labeled 
DP1 domain of STIP1.  
(B) Amino acid sequence of DP1 domain with unassigned residues colored red. The N-




2.3.3 Monomeric state of STIP1 and TPR2A 
Monomeric and dimeric models of STIP1 have been proposed for the biological 
unit in solution [15, 36-38]. The TPR2A domain of STIP1 has been suggested as the 
minimal fragment of STIP1 required for dimerization [36, 38-40]. The isolated TPR2A 
domain has been reported to migrate as a dimer. Thus, we sought to determine the 
structural unit of STIP1 and TPR2A to distinguish between monomeric and dimeric 
models of TPR2A. Gel filtration of the TPR2A domain migrated as a monomer in 
solution when compared to retention volumes of globular proteins of known molecular 
weight (Figure 2.7A).  
Analytical ultracentrifugation experiments were conducted to confirm the 
monomeric state of STIP1 andTPR2A in solution. STIP1 presented a Mobs value of 55.3 ± 
0.9 kDa, reasonably close to the predicted molecular weight of 62.6 kDa and consistent 
with current monomeric models (see chapter 4). The TPR2A domain sedimented with a 
Mobs of 17.2 ± 0.2 kDa, which is in close agreement to the inferred molecular weight of 
monomeric TPR2A of 16.2 kDa based on the amino acid sequence (Figure 2.7B). These 







Figure 2.7. TPR2A behaves as a monomer in solution. 
(A) Size-exclusion chromatography elution profile of TPR2A monitored by protein absorbance at 280 nm. TPR2A eluted as a single 
species consistent to a monomer when compared to elution volumes of globular proteins of known molecular weight. (B) 




2.3.4 Stability of TPR1 and TPR2A 
Physiological ligands of STIP1 stability have been reported to vary under 
different pH conditions. The majority of studies of the cellular prion protein (PrP) are 
conducted under low pH conditions, thus we aimed to assess the stability of the TPR1 
and TPR2A domains under various conditions to optimize future binding studies (See 
Chapter 3).  
The stability of TPR1 and TPR2A domains was investigated by circular 
dichroism at various pH. Deconvolution of the TPR1 and TPR2A predicted 72.6 and 
73.8% α-helical structure at neutral pH, respectively, which is in close agreement with 
the x-ray crystallographic structures previously solved (Figure 2.8 and 2.9A). A decrease 
in α-helical character and increase in the predicted disordered regions of the protein was 
observed at low pH (~5). As well, thermal denaturation of both TPR1 and TPR2A 
indicated a decrease in stability at low pH compared to neutral conditions indicated by a 
decrease in the melting temperatures of approximately 10°C for both domains (Figure 2.8 
and 2.9B). These results indicate binding studies at neutral pH conditions would be 
optimal with TPR1 and TPR2A, which is at odds with most PrP studies being conducted 
at pH 5 [41, 42]. However, low salt conditions at neutral pH have been reported for PrP 




Figure 2.8. TPR1 domain is predominately α-helical and demonstrates increased stability at neutral pH. 
(A) CD spectra of TPR1 collected at pH 5 (red), pH 6 (blue) and pH 7 (black). (B) Thermal melts of TPR1 monitored by CD at 220 





Figure 2.9. TPR2A domain is predominately α-helical and demonstrates increased stability at neutral pH. 
(A) CD spectra of TPR2A collected at pH 5 (red), pH 6 (blue) and pH 7 (black). (B) Thermal melts of TPR2A monitored by CD at 
220 nm collected at pH 5 (red), pH 6 (blue) and pH 7 (black). 
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2.3.5 Hsp90 binding to TPR2A 
1H-15N HSQC of the TPR2A domain collected in the absence and presence of 
equimolar concentrations of Hsp90 C-terminal peptide produced large chemical shift 
changes indicative of binding (Figure 2.10A). The magnitude of chemical shift 
perturbations for traceable residues was calculated from the combined chemical shift 
changes in 1H and 15N dimensions (Δω = |0.2 * Δ15N| + |Δ1HN|) in ppm. Residues 
demonstrating the largest combined chemical shift changes (> 0.1 ppm) clustered to the 
binding interface of the TPR2A-Hsp90 C-terminal peptide complex (Figure 2.10B). 
Residues mapping to the carboxylate clamp (K229, N233, N264, K301 and R305) which 
are involved in electrostatic interactions with the ‘EEVD’ motif based on the solved 
crystal structure, demonstrated large chemical shift change further confirming the 





Figure 2.10. Chemical shift mapping of Hsp90 C-terminal peptide binding to 
TPR2A agrees with the solved crystal structure for the complex. 
(A) Overlay of 1H-15N HSQC spectra of TPR2A in the absence (black) and presence 
(red) of equimolar concentrations of Hsp90 C-terminal peptide. (B) Crystal structure of 
TPR2A in complex with Hsp90 peptide (PDB: 1ELR) with traceable chemical shift 
changes upon addition of Hsp90 peptide colored based on the magnitude of the combined 









STIP1 is composed of three TPR (TPR1, TPR2A and TPR2B) and two aspartate-
proline rich (DP1 and DP2) domains that function in a coordinated manner during Hsp70 
and Hsp90 client protein refolding [12]. Initial peptide recognition by Hsp70 is facilitated 
by the TPR1 domain, which is then transferred to TPR2B in the presence of Hsp90 by a 
flexible linker adjacent to the DP1 domain [15], presumably to mediate transfer of the 
client-bound Hsp70 to the HSP90 binding site in TPR2A. The minimal functional unit for 
glucocorticoid receptor activation in vivo spans the C-terminal TPR2A-TPR2B-DP2 
fragment [14, 44]. Hsp90 clients include a number of proto-oncogenic tyrosine kinases 
and receptors including cyclin-dependent kinase-4, B-Raf, EGFR, HER2 and Bcr-Abl 
[45-49]. Traditional approaches in Hsp90 targeting involve small molecular inhibitors 
such as geldanamycin (GA) and the 17-AAG derivatives, which bind the ATP-binding 
pocket of Hsp90. However; this class of therapeutics has demonstrated high levels of 
toxicity in patients including anorexia, nausea, hepatoxicity [50].  
An alternative approach has been explored in small molecule inhibitors that disrupt 
Hsp90 interaction with TPR2A. These molecules share a 7-azaoeridine ring core and 
inhibited Her2-positive human breast cancer cell lines [20]. The greater than 90% 
assignments of the TPR domains of mammalian STIP1 can be used to screen and 
optimize potential inhibitors of Hsp70 and Hsp90 binding and serve as potential cancer 
therapeutics. Previous structural NMR studies have focused on the yeast STIP1 
homologue that shares only approximately 40% sequence identity. Thus, the mouse 
STIP1 assignments may be of great benefit in this approach as it is nearly identical to 
human STIP1.  
  
69 
The DP1 and DP2 domain solution structures have recently been solved by NMR, 
which revealed a novel α-helical fold [14]. The yeast and mouse STIP1’s share 
approximately 40% sequence identity; however, SSP score analysis of the 13Cα and 13Cβ 
chemical shift deviations revealed a predicted α-helical arrangement of five α-helices 
separated by short interconnecting linkers and is in agreement with the yeast structure 
[14, 35]. The DP2 assignment may be used in the study of protein-protein interactions 
between DP2 and potential ligands. As well, disruption of the recently identified 
interactions with TPR2B of STIP1 may be of great interest, as the minimal functional 
fragment of STIP1 spans the TPR2A-TPR2B-DP2 domains and DP2 contacts with these 
TPRs may serve as another possible strategy to inhibit STIP1 function in oncogeneic 
client folding [15]. 
Previous studies have disputed the monomeric state of STIP1 proposing alternate 
dimeric models as the biological unit [36-38]. Gel filtration chromatography and 
sedimentation equilibrium experiments presented here confirmed the monomeric state of 
STIP1 and TPR2A. Current models strongly suggest a monomeric model for STIP1 Hsp 
coordination with individual TPR domains facilitating concurrent interactions of Hsp70 
and Hsp90 [14, 15, 40]. Previous discrepancies may have arisen due to the elongated 
structure of STIP1 domain arrangement, deviating from predicted globular proteins [14, 
51]. 
To optimize conditions for STIP1 domains identified to bind PrPC (TPR1 and 
TPR2A) (See chapter 4), their stability was assessed at various pH. Most PrPC studies are 
conducted at low pH (~5); however, TPR stability appeared diminished at low pH based 
on circular dichroism. Thus, future studies with PrPC may benefit from neutral conditions. 
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Indeed, PrPC interactions and structural studies have been reported at neutral pH in low 
salt conditions.  
The assigned backbone assignments of the TPR (TPR1, TPR2A and TPR2B) and DP 
(DP1 and DP2) assignments provide the foundation for future NMR studies involved in 
STIP1 ligands such as inhibitors of the Hsp90 pathway and the cellular prion protein 
(PrPC). Stability screening of the PrPC interacting domains (TPR1 and TPR2A) will 
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3 Domains of STIP1 responsible for regulating the PrPC-
dependent amyloid-β oligomer toxicity 
3.1 Introduction 
Neurotoxic assemblies composed of soluble oligomers of the amyloid-beta 
peptide (AβO), derived from the sequential proteolytic cleavage of the amyloid precursor 
protein (APP), are thought to be critical for neurotoxicity in Alzheimer’s disease (AD) [1, 
2]. AβOs interact with numerous neuronal receptors or channel proteins resulting in 
impairment of synaptic plasticity, oxidative stress, disruption of Ca2+ homeostasis, 
inhibition of long-term potentiation (LTP) and neuronal cell death [3-6].   
The cellular prion protein (PrPC) is a high affinity AβO receptor that has garnered 
interest in relation to AβO-induced synaptic dysfunction [6-8]. PrPC is a highly expressed 
cell surface glycoprotein which functions as a membrane scaffold for numerous ligands 
resulting in modulation of cellular signaling events [9]. PrPC-AβO complex formation is 
coupled to activation of Fyn kinase through mGluR5 resulting in deregulation of NMDA 
receptors and calcium signaling [10-12].  Residues 23-27 and 95-110 of the disordered N-
terminal region of PrPC have been proposed to mediate AβO binding [6, 13, 14]. 
Moreover, impairment of binding to residues 95-110 seems to alleviate AβO 
neurotoxicity [6, 7]. While PrPC is not essential for all AβO-induced deficits, inhibition 
of hippocampal LTP, impaired synaptic plasticity, loss of dendritic spines and neuronal 
cell death seem to be PrPC-dependent [6, 8, 15]. Disruption of AβO binding by antibodies 
directed against PrPC mitigate AβO induced neurotoxicity, suggesting that modulation of 
AβO-PrPC interactions may be of therapeutic value in AD [7, 16-18]. Notably, a ligand of 
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PrPC, stress-inducible phosphoprotein 1 (STIP1), can inhibit AβO toxicity in neurons in a 
PrPC-dependent manner [19]. Moreover, decreased levels of STIP1 in mammalian 
neurons or knockdown of STIP1 in C. elegans increases the toxicity of amyloid peptides 
[19, 20]. 
STIP1 is a cellular cochaperone that coordinates Hsp70 and Hsp90 interactions 
during folding of various cell cycle regulators and signal transduction proteins [21]. 
Interestingly, Hsp70, Hsp90 and STIP1 all can be secreted to the extracellular space 
through non-canonical pathways by extracellular vesicles, where they can increase 
cellular resilience by acting as extracellular chaperones or by signaling via membrane 
receptors [22-25]. In particular, STIP1 is secreted by astrocytes into the extracellular 
space, where it functions as a signaling molecule through PrPC [22, 26]. Complex 
formation with PrPC induces neuroprotective and neuroproliferative signaling via PKA 
and ERK pathways, respectively [27, 28], which is initiated by Ca2+ influx through the α7 
nicotinic acetylcholine receptor (α7nAChR) in hippocampal neurons [29]. 
STIP1 is a modular protein composed of three structurally related 
tetratricopeptide repeat domains (TPR1, TPR2A and TPR2B), as well as two aspartate-
proline-rich regions (DP1 and DP2). Hsp engagement is facilitated through sequential 
interactions with the TPR domains. Binding of Hsp70 and Hsp90 to the TPR1/TPR2B 
and TPR2A domains of the cochaperone STI1P, respectively, allows the transfer of 
clients from Hsp70 to Hsp90 [21, 30-33]. However, recent work suggests that interaction 
between STIP1 and Hsp90 is comprised of more extensive interactions with the N-
terminal domain and middle domain of Hsp90 [34, 35]. Previous work indicated that 
amino acids 113-128 within PrPC are critical for STIP1 interaction [19, 26, 36]. Giving 
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that STIP1 could potentially interact with PrPC, Hsp90 and Hsp70 in the extracellular 
space, and this may modulate AβO toxicity, it is of importance to understand these 
protein interactions at the molecular level.  
Here we provide structural insights into the roles of individual domains of STI1P in 
interacting with PrP as well as in inhibiting the AβO-PrP binding. In addition, the 
potential of complex formation between STIP1, PrP, and Hsp90 is explored. Our results 
reveal multiple domain interactions between STIP1 and PrP are involved in complex 
formation and that the Hsp-interacting domains, TPR1 and TPR2A, directly inhibit AβO 
binding to PrP and neuronal toxicity. In addition, we show that Hsp90 is able to influence 
the interaction of STIP1 with PrP, inhibiting the neuroprotective role of STIP1 against 
AβO insult. 
3.2 Materials and methods 
3.2.1 Protein expression and purification 
pDEST17 expression vectors (Invitrogen) encoding various mouse STIP1 
domains (i.e. full-length STIP1, TPR1 (residues 1 -118), DP1 (residues 119-216), TPR2A 
(residues 217-352), TPR2B (residues 353-480) and DP2 (residues 481-542)) with an 
additional N-terminal tobacco etch virus (TEV) cleavable 6xHis tag were transformed 
into Escherichia coli (E. coli) BL21 (DE3) pLysS strain. E. coli were grown in standard 
M9 minimal media at 37 oC to an OD600 of 0.9, at which point over-expression was 
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Temperature was 
reduced to 22 oC and cultures were grown overnight. 
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Proteins were initially purified by Ni2+-affinity chromatography using Ni 
Sepharose 6 Fast Flow beads (GE Healthcare). 6xHis tag was cleaved by incubation with 
6xHis tagged TEV overnight at room temperature. Following cleavage, TEV and 6xHis 
tag were removed by an additional Ni2+-affinity chromatography purification [37]. For 
nuclear magnetic resonance (NMR) spectroscopy, cells were grown in standard M9 
minimal medium supplemented with 1 g/L 15N-labeled ammonium chloride. Proteins 
were flash-frozen in liquid nitrogen and stored at -80 oC for no longer than a month. All 
NMR studies were conducted with freshly prepared protein.  
N-terminal 6xHis tagged recombinant mouse PrP (23-231), (90-231) and (23-95) 
in pRSETA was graciously provided by Dr. Kurt Wüthrich (ETH Zurich, Zurich, 
Switzerland). Plasmids were transformed into E. coli BL21 (DE3) and cultures were 
grown in lysogeny broth (LB) to an OD600 of 0.9. Expression was induced by the addition 
of 1 mM IPTG and cultures were grown overnight at 22 oC. Inclusion bodies were 
solubilized in 8 M urea containing 25 mM Tris, 500 mM NaCl, pH 7.5 and the resultant 
denatured protein was purified using Ni2+-affinity chromatography. Solubilized protein 
was refolded by dialysis against 10 mM sodium acetate, pH 5. Purified protein was 
exchanged into 10 mM HEPES, pH 7, and the N-terminal 6xHis tag was cleaved by 
overnight incubation with thrombin (Haematologic Technologies Inc.). Thrombin was 
then removed by incubation with Benzamidine Sepharose 4 Fast Flow (GE Healthcare). 
pET28 vectors encoding Hsp90β containing an N-terminal 6xHis tag separated by 
a thrombin cleavage site (kindly provided by Dr. Johannes Buchner, Center for integrated 
protein science (CIPSM) at the Department Chemie, Technische Universität München, 
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Germany) were purified as described in [35]. Plasmid was transformed in E. coli BL21 
(DE3) and cultures were grown in LB to an OD600 of 0.9 and induced with 1 mM IPTG. 
Temperature was dropped to 30 °C and cultures were grown overnight. Bacterial pellets 
were resuspended in 40 mM potassium phosphate, 400 mM KCl, 5 mM ATP, 1 mM 
MgCl2, 6 mM imidazole, pH 8, and lyzed by French press at 10,000 psi. The resultant 
protein was purified using Ni2+ chromatography. Eluted fractions containing Hsp90β 
were combined and cleaved overnight by incubation with thrombin at 4 °C. Hsp90β was 
further purified by gel filtration chromatography with a Superdex S200 column 
equilibrated in 40 mM HEPES, 150 mM KCl, 5 mM MgCl2, pH 7.5. 
AβOs were prepared from Aβ1-42 (rPeptide) as described previously [19]. Briefly, 
Aβ1-42 was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) and SpeedVac 
centrifuged generating peptide films. Aβ1-42 films were first re-suspended in DMSO to a 
concentration of 1 mM and diluted in PBS to a final working concentration of 100 µM or 
150 µM for NMR experiments. Peptides were incubated for 24 hours at 4 °C and stored 
at -80 °C or used immediately.   
3.2.2 NMR spectroscopy 
Experiments were performed on a Varian Inova 600 MHz NMR spectrometer 
equipped with xyz-gradient triple resonance probe at 25 °C in 5 mM sodium phosphate, 
pH 7. Data were processed with NMRPipe and analyzed using NMRView [38, 39]. 
Chemical shift changes were mapped onto PrP (90-231) structure based on a previously 
completed amide assignment (BMRB 16071 deposited in the BioMagResBank 
(http://www.bmrb.wisc.edu))[40]. Binding of preformed AβOs to PrP (90-231) and (23-
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95) was observed by 1H-15N HSQC spectra collected in the presence and absence of 
equimolar concentration (~85 µM) of AβO. 
Backbone amide resonance assignments for TPR1 and TPR2A were obtained 
from the BioMagResBank under accession numbers 18691 and 18689, respectively [37]. 
1H-15N HSQC spectra of 15N-labelled TPR1 (50 µM) and TPR2A (50 µM) were collected 
in the absence and presence of PrP(23-231) (50 µM). The magnitude of chemical shift 
perturbations for traceable residues was calculated from the combined chemical shift 
changes in the 1H and 15N dimensions (Δω (ppm) = |0.2 * Δ15N| + |Δ1HN|) and mapped 
onto the crystal structures of TPR1 (PDB: 1ELW) and TPR2A (PDB:1ELR) [30]. 
3.2.3 Protein-protein binding assay 
10 µg of full-length PrP or N-terminal PrP (23-95) were immobilized onto Falcon 
96-well polystyrene plates by incubation overnight at 4 oC. Non-specific sites were 
blocked by incubation at room temperature for 1 hour with PBS-T (0.05%) containing 
1% BSA. Plates were extensively washed with PBS-T and incubated with increasing 
concentrations of STIP1, different STIP1 domains, or Hsp90 for 1 hour. Following 
washing, bound proteins were detected using polyclonal antibodies directed towards 
STIP1 (1:10,000) in PBS-T. After subsequent washing, wells were probed with 
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (1:5000) (Bio-Rad) for 1 hour. 
The signal was visualized using o-phenylenediamine (OPD) and absorbance was 
measured at 495 nm by microplate reader. 
For assessing PrP influence on Hsp90 binding to STIP1, polystyrene plates were 
covered with 10 µg of STIP1 and blocked as described above. After thorough washing, 
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plates were incubated with various concentrations of PrP for 1 hour at room temperature, 
followed by incubation with 2 µM Hsp90 for 1 hour. After subsequent washing, wells 
were probed with rabbit anti-Hsp90 (1:1000, Cell Signaling) in PBS-T and bound Hsp90 
was detected as outlined above. 
TPR1 was labeled with Fluoroscein-5-Maleimide (Invitrogen) as per 
manufacturer’s instructions to investigate competition of binding between TPR domains 
to PrP. PrP was adsorbed on to black polystyrene plates as described above. Plates were 
incubated with 1 µM fluorescein labeled TPR1 in the presence of various concentrations 
of TPR2A. Following washing, fluorescence was measured at excitation and emission 
wavelengths of 485/535 nm, respectively. 
3.2.4 Surface plasmon resonance (SPR) 
All SPR experiments were performed using a Biacore X system equipped with a 
CM 5 sensor chip (GE Healthcare). The chip was uniformly coated with PrP (23-231) 
using a standard amine-coupling method to an SPR signal of ~7000 resonance units 
(RU). Ligands were injected in 10 mM HEPES, 150 mM NaCl, pH 7, over an association 
period of 7 minutes at a flow rate of 5 µL/min. Off-kinetics were measured for an 
additional 2 minutes following the end of sample injections. The CM5 chip surface was 
regenerated using a 10 mM hydrochloric acid pulse for 1 minute at a flow rate of 100 
µL/min between ligand injections.   
3.2.5 Primary neuronal culture 
Primary cultures of hippocampal neurons were obtained from E17.5 brains of 
wild-type (Prnp+/+) mice from a C57BL6 background and prepared as previously 
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described [19]. Hippocampi were aseptically dissected in HBSS (Invitrogen) and cells 
were dissociated in 0.25% trypsin at 37 oC for 20 minutes. Proteolysis was inactivated by 
re-suspension and dissociation of cells in Minimum Essential Media (MEM) (Invitrogen) 
supplemented with 10% Fetal Bovine Serum, penicillin (100 IU), streptomycin (100 
µg/mL) and glucose (0.5%). Cultures were maintained on poly-lysine-coated coverslips 
or plates in Neurobasal Media (Invitrogen) supplemented with 2% B-27 (Invitrogen), 
penicillin (100 IU), streptomycin (100 µg/mL) and L-glutamine (500 µM). Half of the 
culture media was replaced every 3-4 days for the duration of the culture. 
3.2.6 Cell death and viability assay 
Hippocampal cultures (105 cells/dish) were maintained for 11 days in vitro (DIV) 
then incubated with 1 µM AβO alone or in the presence of STIP1 (1 µM), TPR1 (2 µM), 
TPR2A (2 µM) or DP1 (2 µM) for 48 hours. Cell death was assayed using LIVE/DEAD 
Viability/Cytotoxicity Kit for mammalian cells (Invitrogen) as described by the 
manufacturer. NIH ImageJ Cell Counter plug-in was used to calculate percentage of dead 
cells (number of dead cells / (number of dead cells + number of viable cells)). For Hsp90 
and AβO co-incubation experiments, cell cultures were incubated in the presence or 
absence of Hsp90 (2 µM) and AβO (1 µM) with various concentrations of STIP1 (0-600 
nM) and incubated for 48 hours. Cell death was assayed as described above.  
3.2.7 AβO binding to primary hippocampal neurons 
13 DIV cultured neurons (6 x 104 cells/dish) were treated for 15 minutes with 200 
nM AβO alone or in the presence of 500 nM STIP1 or 1 µM TPR1, TPR2A and DP1 at 
37 oC. Following incubation, cells were washed with KRH buffer (125 mM NaCl, 5mM 
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KCl, 1.8 mM CaCl2, 2.6 mM MgSO4, 10 mM glucose, 5 mM HEPES, pH 7.2). Cells 
were fixed with 4% paraformaldehyde for 20 minutes, washed with PBS, permeabilized 
with 0.5% Triton X-100 in PBS for 5 minutes and blocked with 5% BSA (Sigma-
Aldrich) in PBS for 1 hour at room temperature. Coverslips were incubated with 
antibodies against γ-tubulin (1:500; Abcam) and amyloid-β (6E10, 1:350; Covance) 
overnight at 4 oC. γ-tubulin and amyloid-β were detected by subsequent incubation with 
secondary Alexa Fluor-488 and Alexa Fluor-633-conjugated antibodies (Invitrogen), 
respectively, for 1 hour at room temperature. Immunofluorescence was detected on an 
LSM510 confocal microscope equipped with a 63x/1.4NA oil-immersion objective lens. 
The resultant fluorescence from neurites was integrated using NIH ImageJ software.    
3.3 Results 
3.3.1 Mapping of AβO interface on PrP 
Previous studies have revealed that residues 95-110 of PrPC play a pivotal role in 
mediating the interaction with AβO [6, 13, 16]. To refine the AβO binding-site on PrP in 
a residue specific basis, we performed 1H-15N-HSQC experiments on 15N-labelled PrP 
(90-231) in the absence and presence of preformed AβO at a 1:1 molar ratio (Figure 
3.1A). A significant decrease in signal intensity was observed for amide resonances 
spanning residues 90-110 of the disordered N-terminal of PrP (Figure 3.1C), while no 
new NMR peaks were observed in the PrP spectrum upon the addition of AβO. This loss 
in signal intensity is likely due to peak broadening resultant from residues 90-110 binding 
a large molecular weight species of AβO. No significant systematic changes in intensity 
were observed for C-terminal resonances, suggesting the AβO binding site is highly 
localized to the region spanning residues 90-110 of PrP (90-231) (Figures 3.1B and 
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3.1C). The greatest decreases in peak intensity were observed in a glycine-rich region N-
terminal of the sequence (residues 91-100). Interestingly, small but notable chemical 
shifts were observed for C-terminal residues Leu125, His140, Gly142, Asn174 Val180, 
Asn181, His187, Thr188 and Val189. These changes are likely due to weak transient 
interactions with AβO or moderate conformational changes in PrP upon AβO binding. 
Unfortunately, we were unable to assign the N-terminal of PrP, residues 23-95, due to the 
high sequence redundancy and signal overlap of the spectrum. However, no significant 
intensity changes or chemical shift perturbations were seen in the visible peaks of the 
disordered N-terminal fragment PrP (23-95) in the presence of AβO (Figure 3.1D), which 





Figure 3.1. NMR reveals AβO associate with PrP residues 90-110. 
(A) 1H-15N HSQC spectra of PrP (90-231) in the absence (black) and presence (red) of  mature Aβ1-42 oligomers at a 1:1 ratio. 
Residues that demonstrate a change in intensity (black arrows) or chemical shift changes (blue arrows) are noted. (B) Sample of one-
dimensional traces of peak intensity presented in (A). Residues 90-231 show a loss in signal intensity (Q91) while C-terminal residues 
remain unchanged (E221). (C) Normalized peak intensity of PrP (90-231) plotted against residue number. (black line) Normalized 
peak intensity level expected if no interaction took place between PrP (90-231) and Aβ1-42 oligomers. (red line) Average normalized 
intensity decrease for all residues of PrP (90-231).  (D) Normalized peak intensity of N-terminal PrP (23-95) peaks resolved in the1H-
15N HSQC spectra in the presence of AβO.  Due to signal overlap and sequence redundancy, the identity of the residues represented 
by each peak could not be determined and the thus were assigned an arbitrary number. (black line) Normalized peak intensity level 
expected if no interaction took place between PrP (23-95) and Aβ1-42 oligomers. (red line) Average normalized intensity decrease for 
all peaks of PrP (23-95). 
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3.3.2 Identification of STIP1 binding domains of PrP 
We next sought to identify domains of STIP1 that bind PrP and the respective 
regions of PrP that mediate the interactions. Previous studies have identified the TPR2A 
domain of STIP1 as the major interaction site for PrP [19, 26, 36]. However, additional 
regions of STIP1 may be involved in PrP binding due to the modular structure of STIP1 
and the structural similarity shared between its TPR domains. Of particular interest were 
STIP1 domains that specifically bind to PrP (90-231), since they may impair PrP-AβO 
complex and provide a mechanistic basis for STIP1 neuroprotective properties against 
AβO insult [19]. We tested binding of STIP1 and its domains using a multi-well protein-
binding assay. The domain boundaries of STIP1 are shown in Figure 2A. We confirmed 
that STIP1 specifically bound PrP with high affinity (Figure 3.2B), Kd = 186±15 nM), 
which is in agreement with previous studies [26]. Probing full-length PrP with individual 
domains of STIP1 revealed that TPR1 (Kd = 1.2±0.2 µM) and DP1 (Kd = 600±50 nM), in 
addition to the previously reported TPR2A (Kd = 800±130 nM) domain, can also interact 
with PrP with comparable affinity, albeit lower than the affinity of full length STIP1 
(Figure 3.2C). The DP1 domain of STIP1 was capable of interacting in a specific and 
saturable manner with an N-terminal fragment of PrP (23-95), whereas the other domains 
(TPR1 and TPR2A) did not (Figure 3.2D). The results strongly suggest that DP1 interacts 
with the disordered N-terminal fragment of PrP (23-95), while PrP (90-231) binds TPR1 
and TPR2A. The result is consistent with finding of previous studies showing that 
residues 113-128 of mouse PrP is responsible for mediating the interaction with the 
TPR2A domain of STI1P [26]. 
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Since TPR1 and TPR2A both bind the C-terminal fragment of PrP (90-231), we 
investigated whether these domains can bind simultaneously or compete for binding to 
PrP. TPR2A was capable of displacing fluorescently labeled TPR1 from its complex with 
PrP in a concentration-dependent manner suggesting that binding of TPR1 and TPR2A to 
PrP is mutually exclusive (i.e. the TPR1 and TPR2A binding sites on PrP are either 




Figure 3.2. DP1, TPR1 and TPR2A associate with PrP. 
(A) Domain structure of STIP1 illustrating domain boundaries of three TPR (TPR1, TPR2A and TPR2B) and two DP (DP1 and DP2) 
domains. (B) Polystyrene plates were pre-coated with 10 µg of PrP (23-231). Wells were probed with various concentrations of STIP1 
(B) or STIP1 domains (C). STIP1 or domain immunoreactivity was detected using polyclonal anti-STIP1 antibodies and binding is 
presented as OD495 values. (D) N-terminal PrP (23-95) was incubated with increasing concentrations of STIP1 domains. Binding of 
the domains was detected as in (B and C) (n=3). (E) Immobilized PrP (23-231) was incubated with 1 µM fluorescein-labeled TPR1 in 
the presence of various concentrations of TPR2A (n=4). Fluorescence of bound TPR1 was measured at excitation and emission 




3.3.3 TPR1 and TPR2A prevent AβO binding to PrP 
We have previously demonstrated that the TPR2A domain of STIP1 is able to 
inhibit AβO binding to PrP, albeit with lower potency than full length STIP1 [19]. Given 
that TPR1 and TPR2A can both bind to the C-terminal part of PrP (residues 90-231), we 
investigated whether TPR1 can modulate AβO-PrP binding by surface plasmon 
resonance (SPR). AβO injections showed a dose-­‐dependent increase in response 
monitored by SPR indicating binding (Figure 3.3A). Co-­‐injection of STIP1 (62.5 nM) 
with a constant concentration of AβO showed an appreciable decrease in the response 
signal, suggesting inhibition of AβO binding to PrP. When co-injected with 125 nM 
STIP1, the response from AβO was equal to that of an injection of 125 nM STIP1 alone, 
suggesting complete inhibition of AβO binding (Figure 3.3B). Injections of TPR1 or 
TPR2A domains also inhibited AβO binding to PrP in a dose-dependent manner, albeit at 
higher concentrations than full-length STIP1 (Figures 3.3C and 3.3D, respectively). DP1, 
which binds the N-terminal region of PrP (residues 23-95), did not have any effect on 
AβO signals, consistent with this region being dispensable for AβO binding to PrP 
(Figure 3.3E). Injection of each domain individually produced no detectable signal likely 
due to their small size and sensitivity of the instrument (data not shown). These results 
suggest that both the TPR1 and the TPR2A domains of STIP1 contribute to the direct 





Figure 3.3. TPR1 and TPR2A, but not DP1, inhibit AβO binding to PrP(23-231) in vitro. 
PrP (23-231) was covalently immobilized on to a CM5 sensor chip. (A) Sensograms were collected for various AβO concentrations 
binding to PrP (23-231). (B-E) Binding of AβO (2 µM) in the presence of increasing concentrations of STIP1 (B), TPR1 (C), TPR2A 
(D) or DP1 (E). 
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3.3.4 TPR1 and TPR2A inhibit AβO binding and toxicity in neurons 
STIP1 is a neuroprotective regulator of AβO toxicity in hippocampal neurons	  and 
TPR2A domain by itself can reproduce this effect [19]. We therefore investigated 
whether in vitro inhibition of AβO binding to PrP by TPR1 can also translate to a 
beneficiary response in cultured primary mouse hippocampal neurons. Ectopic treatment 
of neurons with recombinant STIP1, TPR1 or TPR2A domains in the presence of AβO 
significantly decreased AβO binding to neuronal cell bodies compared to treatment with 
AβO alone (Figures 3.4A and 3.4B). Co-treatment of neuronal cultures with AβO and 
DP1 resulted in no visible effect on the amount of AβO bound to neurites. These 
observations reflected our in vitro SPR results where only the TPR1 and TPR2A 
domains, but not DP1, were able to inhibit AβO binding to PrP in a concentration-
dependent manner. To assess if the decrease in AβO binding translated to inhibition of 
AβO cytotoxicity, primary hippocampal neurons were treated with AβO in the presence 
or absence of STIP1, TPR1, TPR2A or DP1 and incubated for 48 hours before assessing 
the number of dead cells. AβO treatment alone increased cell death by ~15% compared to 
basal levels. Co-treatment with STIP1, TPR1 or TPR2A rescued neuronal death from 
AβO induced toxicity (Figure 3.4C). No discernible effect on cell viability was seen in 







Figure 3.4. STIP1, TPR1 and TPR2A inhibit AβO binding and toxicity in primary mouse hippocampal neurons. 
 (A) Representative images of 13 DIV neurons stained for γ-tubulin (red) and β-amyloid (green) after treatment with AβO in the 
presence of STIP1, TPR1, TPR2A or DP1. (B) Quantification of A. (C) Comparison of neuronal cell death after 48 hours treatment 
with AβO (1 µM) alone or in the presence of STIP1 (1 µM), TPR1 (2 µM), TPR2A (2 µM) or DP1 (2 µM). Experiments were 
analyzed by one-way ANOVA, followed by Tukey’s post hoc test. ***P < 0.001, (n=3). 
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3.3.5 Mapping of TPR1 and TPR2A interfaces mediating PrP 
binding 
To gain molecular understanding of the STIP1-PrP interactions, NMR 
spectroscopy was used to map the binding interfaces of PrP on TPR1 and TPR2A on a 
residue-specific manner. 1H-15N HSQC spectra of TPR1 and TPR2A showed comparable 
amplitude of chemical shift perturbations upon addition of PrP (Figures 3.5A and 3.5C). 
Resonances undergoing fast exchange (i.e. chemical shift difference between the free and 
bound states is small compared to the rate of exchange between these two states) were 
traced upon titration of PrP and were mapped onto the crystal structures of TPR1 and 
TPR2A (Figures 3.5B and 3.5D). Notable chemical shift changes were observed for 
residues Asp70, Trp71, Gly98, Lys100, His101 and Ala103 of TPR1, which form a 
contiguous patch on the surface of the C-terminal part of the TPR1 structure (Figure 
3.5B). In contrast, the TPR2A binding interface for PrP is more extensive, extending 
diagonally across a hydrophobic cradle-shaped groove on one side of the TPR2A 
molecule. Interestingly, this cradle-shaped groove is reserved for binding of the C-
terminal peptide of Hsp90 to fulfill STIP1 cochaperone function during protein client 
folding [30]. While critical contacts between TPR2A and Hsp90 C-terminal peptide made 
by the carboxylate clamp (Lys229, Asn233, Asn264, Lys301, Arg305) of TPR2A did not 
show the largest chemical shift changes upon binding of PrP, the partial overlap between 
the Hsp90 and PrP binding interfaces suggests that Hsp90 and PrP may regulate each 
other’s binding to STIP1 (Figure 3.6A). Therefore, we examined the potential for 





Figure 3.5. NMR indicates distinct regions of TPR1 and TPR2A interact with PrP(23-231). 
(A) Graphical representations of chemical shift changes observed in 1H-15N spectra of 15N-labelled TPR1 or (C) TPR2A in the 
presence of PrP(23-231). (B) Combined chemical shift changes mapped on to the crystal structure of TPR1 (PDB:1ELW) or (D) 
TPR2A (PDB:1ELR). The protein structure images are generated using the Chimera molecular graphics software [54]. 
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STIP1 was adsorbed onto polystyrene plates and probed with PrP. Following 
thorough washing of the complex; plates were incubated with a constant amount of 
Hsp90 (4 µM) and bound Hsp90 was detected using antibodies directed against Hsp90. 
Intriguingly, by increasing the concentration of PrP we achieved a saturable increase in 
Hsp90 binding to the plate (Figure 3.6B). In contrast, no Hsp90 binding was detected to 
PrP immobilized onto a polystyrene plate in the absence of STIP1 (Figure 3.6C). These 
data suggest that PrP binding to STIP1 may induce conformational changes in the 
complex, which in turn may increase the recruitment of Hsp90. 
To investigate the potential relevance for the ternary complex formation of STIP1, 
Hsp90 and PrP in AβO toxicity, primary mouse hippocampal neurons were incubated in 
the presence of AβO (1 µM) and sub-optimal concentrations of STIP1. STIP1 caused a 
dose-dependent decrease of AβO-induced cell death (Figure 3.6D). However, addition of 
excess recombinant Hsp90 (2 µM) prevented STIP1 neuroprotection against AβO (Figure 
3.6D). These results suggest that excess Hsp90 is able to block STIP1 neuroprotective 
signaling, potentially by sequestering the protein or by interfering with signaling events 




Figure 3.6. Hsp90 inhibits STIP1 rescue of primary mouse hippocampal neurons 
against AβO induced cell death. 
(A) Chemical shift changes of PrP binding site on TPR2A (top) compared to the solved 
crystal structure of Hsp90 C-terminal MEEVD peptide bound to TPR2A (bottom) 
(PDB:1ELR). Residues of TPR2A involved in electrostatic interactions, hydrogen 
bonding or Van der Waals interactions with Hsp90 peptide are labeled (black). The 
protein structure images are generated using the Chimera molecular graphics software 
[54]. (B) Polystyrene plates pre-coated with 10 µg of STI1P were first incubated with 
increasing concentration of PrP, followed by incubation with Hsp90 (2 µM). Bound 
Hsp90 was detected using polyclonal anti-Hsp90 antibodies. Binding is presented as 
OD495 values (n=3). (C) Polystyrene plates were pre-coated with 10 µg of full-length PrP 
(23-231). Wells were probed with various concentrations of Hsp90, followed by 
detection of bound Hsp90 using polyclonal anti-Hsp90 antibodies. Binding is presented 
as OD495 values (n=3). (D) Comparison of cell death of 13 d neurons after 48 hour 
treatment with AβO (1 µM) and various concentrations of STIP1 (0-600 nM) in the 
presence (red) or absence of HSP90 (2 µM) (black) (n=7). Experiments in the presence or 
absence of Hsp90 were analyzed by two-way ANOVA, followed by Bonferroni’s post 





AβOs have been demonstrated to trigger synaptic dysfunction through interactions 
with several neuronal receptors [3-5, 41]. Numerous studies have identified PrPC as a 
high affinity receptor for AβOs and implicated the interaction in the transmission of 
neurotoxic signaling [6, 15, 17]. Disruption of the PrPC-AβO complex has shown 
therapeutic merit in the reduction of AβO toxicity [7, 19]. We have recently determined 
that the cellular cochaperone and physiological PrPC ligand STIP1 is able to directly 
inhibit AβO binding to PrPC and alleviate synaptic loss, depression of long-term 
potentiation and neuronal cell death [19]. Therefore, understanding how this complex is 
modulated is of importance. 
The studies reported here provide molecular insights regarding the functional 
modules of STIP1 that directly contribute to its recently described protective role against 
AβO neurotoxicity and structural details of regions involved in binding to PrP. Our NMR 
studies revealed significant resonance attenuations in the N-terminal unstructured region 
of PrP encompassing residues 90-110 upon binding of mature preformed AβOs, 
suggesting these residues mediate complex formation. These results are consistent with 
previous observations, which indicated residues centered around 95-110 are essential and 
sufficient for AβO binding to PrP [6, 7, 13, 14]. No significant chemical shift changes 
were observed upon the addition of AβO to N-terminal PrP (23-95). A short highly basic 
charge cluster ‘KKRPK’ located in the far N-terminal of PrP (residues 23-27) has been 
suggested as a secondary AβO binding; however, other groups have reported near 
identical AβO binding levels to PrP (90-231) as wild-type PrP [13, 42]. It is possible the 
charge cluster acts as a secondary binding event following initial association of AβO to 
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the primary binding site (residues 90-110). Thus, residues 23-95 may not participate in 
binding in the absence of the high affinity site, which could explain the lack of large 
chemical shift perturbations of PrP (23-95). Unfortunately, due to high sequence 
redundancy and peak overlap problems owing to its disordered properties, we were 
unable to assign residues 23-95 of PrP constructs. Thus, we cannot rule out the possibility 
of minor, but localized chemical shift changes in residues 23-95 upon AβO titration.  
Small chemical shift changes were noted for C-terminal PrP residues mapping to α-
helices 1 and 2. These changes were much smaller in magnitude than those observed for 
the primary AβO binding site. These findings are unexpected, since the globular part of 
C-terminal portion of PrP is thought to be dispensable in its interaction with AβO. These 
changes may result from conformational alterations in helix 1-helix 2 of PrP upon AβO 
interaction. Alternatively, transient contacts between PrP molecules may be induced upon 
binding to Aβ aggregates, stabilizing these complexes. Indeed, competition experiments 
targeting an epitope spanning residues 131-153 effectively disrupted AβO binding to PrP 
[7].  
Our protein-protein binding assay results showed that full-length STIP1 binds to PrP 
(23-231) with high affinity (Kd ~186 nM), which is in agreement with previous finding 
[26, 36]. Surprisingly, binding of different domains of STIP1 to PrP (23-231) indicated 
that not only previously identified TPR2A, but also the structurally related TPR1 domain 
and the DP1 domain bind PrP with high affinity. TPR2A was capable of displacing TPR1 
binding to PrP suggesting that they have overlapping binding sites or TPR2A is capable 
of occluding the TPR1 binding site on PrP. Interestingly, DP1 domain bound to the N-
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terminal of PrP (residues 23-95), while the TPR domains did not, suggesting their 
binding-site on PrP lies within residues 90-231. The recently solved NMR structures of 
the DP1 and DP2 domains of yeast STIP1 reveal a novel α-helical fold composed of 6 
and 5 helices, respectively [35]. Electrostatic potentials of DP1 illustrate a slightly 
positive groove containing an additional α-helix absent in DP2, which stabilizes 
secondary structure elements in DP1. Consequently, while both DP1 and DP2 share a 
common tertiary structure, these distinct structural differences may indicate the inability 
of DP2 to bind to the N-terminal of PrP.  
Even though the function of the DP domains remains uncertain, the length of the 
linker between TPR1 and TPR2A, which includes the DP1 domain, has recently been 
proposed to facilitate transfer of Hsp90 from TPR1 to TPR2B during protein client 
folding [33]. This is the first study to identify a direct ligand of DP1, suggesting the 
domain may influence STIP1 binding to physiological ligands outside of its cochaperone 
role in client protein refolding.  
We confirmed by SPR the dose-dependent specific interaction between immobilized 
PrP and AβO. Due to the abnormally long dissociation kinetics, consistent with other 
studies, we were unable to quantitatively determine a binding constant for the interaction 
[13, 19, 43]. Thus, the effects of STIP1 and individual domains on AβO were assessed 
qualitatively based on the absolute magnitude of the response change. STIP1 effectively 
inhibited AβO binding to PrP, abolishing the interaction at low nanomolar 
concentrations, as demonstrated previously [19]. TPR2A and TPR1 domains were also 
capable of inhibiting AβO binding to PrP albeit at much greater concentrations than 
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STIP1, in agreement with our previous observations of STIP1 having a greater binding 
affinity than the individual domains alone, supporting the notion of multiple binding 
sites. DP1, the N-terminal PrP-binding domain of STIP1, had no discernible effect on 
AβO binding with full-length PrP, which agrees with C-terminal PrP being the primary 
AβO binding site. While DP1 may not actively disrupt AβO interaction with PrP, it may 
contribute to the greater binding affinity of full length STIP1 binding to PrP and thus its 
efficacy as an AβO inhibitor. Further investigation will be needed to determine the 
molecular basis by which DP1, TPR1, and TPR2A domains inhibit PrP-AβO binding in 
the full-length context.  
AβO binding to neurons leads to cell death and impaired synaptic plasticity through 
multiple signaling pathways [10, 44, 45]. Activation of aberrant NMDAR signaling by 
AβO interaction to PrPC resulting in hyper excitability and activation of Fyn kinase has 
been implicated in dendritic spine loss and neuronal cell death. We found that treatment 
of primary mouse hippocampal neurons with STIP1, TPR1 or TPR2A reduced the 
amount of AβO bound to the neuronal surface. Importantly, decrease in AβO binding 
translated to rescue of neuronal cell death. Consistent with the inability of DP1 to inhibit 
AβO binding in vitro, DP1 had no notable effect on binding of AβO to neurons or on cell 
death. These results suggest that the TPR1 and TPR2A domains of STIP1 may cooperate 
for the neuroprotective effects of STIP1 against AβO insult through PrPC. 
Tetratricopeptide repeat motifs are highly degenerate 34 amino acids sequences 
arranged into helix-loop helix structures forming adjacent anti-parallel helices [46].  The 
high structural similarity between the TPR1 and TPR2A domains and their similar 
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properties in inhibition of AβO binding to PrP led us to investigate whether these two 
regions bind similarly to PrP at the structural level using NMR. Intriguingly, the binding 
interfaces of TPR1 and TPR2A with PrP differ significantly. PrP bound TPR1 in a short 
region encompassing the C-terminus of helix 6 and its respective interconnecting loop 
region with helix 7. This region is far removed from the traditional TPR binding site 
involved in protein-protein interactions. 
The TPR2A interface extends diagonally across a hydrophobic cradle-shaped groove 
on a single face of the TPR2A molecule [30]. Notably, this region overlaps with the 
Hsp90 binding site of TPR2A, which is formed by electrostatic interactions with highly 
conserved carboxylate clamp residues of TPR2A and the C-terminal EEVD motif of 
Hsp90 [30]. Significant chemical shift changes were observed in residues corresponding 
to the carboxylate clamp, as well as in additional residues occupying the cradle-shaped 
groove that binds Hsp90.  
While Hsp90 plays an important role in assisting and maintaining the proper folding 
of many non-natively structured proteins, it has been implicated as detrimental in the 
clearance of hyper-phosphorylated tau and Aβ, the pathological species in AD [47-49]. 
Along with this, Hsp90 inhibitors have been shown to be effective in facilitating tau 
clearance and inhibiting Aβ neurotoxicity in mice [50]. In addition, actively secreted 
Hsp90 also contributes to the regulation of extracellular client proteins [24, 51]. Given 
that both STIP1 and Hsp90 are secreted, it is plausible that extracellular Hsp90 may 
influence STIP1 interaction with PrP in the extracellular matrix or on the cell membrane. 
Interestingly, while the TPR2A interfaces for Hsp90 and PrP binding show large 
overlapping regions, PrP binding to STIP1 appears to promote ternary complex formation 
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with Hsp90. PrP binding to STIP1 has been suggested to induce conformational changes 
in PrP resulting in loss of helical structure [36]. The STIP1 induced unfolding may reveal 
previously buried hydrophobic pockets on PrP, thus mimicking a misfolded protein and 
resulting in the recruitment of Hsp90. Alternatively, Hsp90 binding to TPR2A domain of 
STIP1 may induce structural rearrangements in both proteins, which may hinder STIP1 
signaling through PrP. However; the relationship and potential interplay between STIP1, 
Hsp90 and the PrP is poorly understood and will require further study regarding their 
roles in the extracellular environment and implications in AD. 
STIP1 has traditionally been considered as a cochaperone in the regulation of Hsp70 
and Hsp90 client protein folding, however; strong evidence has revealed its importance 
as a signaling molecule through PrP in neuroprotection [27, 29-31, 35, 52, 53]. The 
modular structure of STIP1 allows for multiple domains to contribute to complex 
formation with PrP, which have a direct influence on its protective role against AβO 
insult. In addition, our studies indicate the possibility of ternary complex formation 
composed of PrP, STIP1 and Hsp90, which may influence STIP1 neuroprotective 
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4 Structural details of STIP1 complex with S100A1 
4.1 Introduction 
The S100-family of proteins comprises approximately 25 members involved in 
several crucial biological processes including calcium (Ca2+) homeostasis, proliferation, 
differentiation, inflammation and apoptosis [1-3]. These proteins are tissue and cell-
specific homo/hetero dimers composed of two EF-hand helix motifs capable of Ca2+ ion 
coordination [4]. Typically upon Ca2+-binding, α-helices III of each subunit undergo a 
significant conformational change exposing a hydrophobic cleft, which represents the 
binding site to various ligands [5]. Thus, S100-family is considered as Ca2+- dependent 
regulators of several cellular pathways through multiple documented protein-protein 
interactions [4]. Altered expression patterns of unique S100 proteins have been noted in 
several disease states including different forms of cancer, cardiomyopathy and 
neurodegenerative diseases such as Alzheimer’s disease (AD) and serve as clinical 
diagnostic biomarkers [6-9]. 
Calcium serves as a ubiquitous signaling molecule in neuronal activation whose 
deregulation is a common hallmark in AD causing synaptic dysfunction[10]. Ca2+ -
binding proteins play an important role in regulating Ca2+ homeostasis and modulating 
protein-protein interactions. Consistent in this capacity, a number of S100-family 
members have been implicated in aberrant AD signaling [6, 11, 12]. S100A1 is 
abundantly expressed in skeletal muscle, cardiomyocytes and neurons [6, 8, 13]. S100A1 
has been found to regulate amyloid precursor protein (APP) processing, tau 
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phosphorylation and Aβ oligomer induced neuronal cell death [14]. In addition, studies 
have revealed roles for S100A1 in the heat-shock protein response, regulating Hsp70 and 
Hsp90 binding to stress-inducible phosphoprotein 1 (STIP1) during client protein 
refolding [15, 16].  
STIP1 is a cellular co-chaperone, which coordinates client protein transfer from 
Hsp70 to Hsp90 during protein folding of various cellular ligands including numerous 
oncogenic kinases and transcription factors [17]. STIP1 is composed of three structurally 
related tetratricopeptide repeat (TPR1, TPR2A and TPR2B) domains and two aspartate 
and proline rich DP (DP1 and DP2) domains. TPR domains are 34-amino acid degenerate 
consensus motifs arranged in tandem forming a series of anti-parallel amphipathic α-
helices [18]. They are common protein-protein interaction modules involved in numerous 
cellular processes including cell cycle regulation, transcription and protein folding [19]. 
TPR2A and TPR2B mediate interactions between the C-terminal EEVD motif of Hsp90 
and through a series of contacts located in the middle domain of Hsp90 [17, 18, 20, 21]. 
Hsp70 coordination involves binding to the TPR1 and TPR2B domains of STIP1.  
S100A1, S100A2 and S100A6 family members have been identified as STIP1 
ligands, forming molecular complexes through interactions with the TPR domains of 
STIP1 [15, 16]. S100A2 and S100A6 association has also been shown to inhibit Hsp70 
and Hsp90 binding to STIP1 in vitro and in cell culture upon Ca2+ stimulation, 
implicating their function in the STIP1-directed protein-folding relay. However, the 
molecular details of S100 binding to STIP1 remain largely unknown.  
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The present study employed NMR, analytical ultracentrifugation and isothermal 
titration calorimetry (ITC) to define the molecular details of S100A1 binding to STIP1. 
Our results reveal that each TPR domain is capable of simultaneous binding to a single 
S100A1 dimer with varying affinities and thermodynamic parameters in the full-length 
STIP1 molecule. Each TPR domain associates with S100A1 through a common binding 
site, spanning α-helices III and IV of S100A1 in a Ca2+-dependent manner. While nuclear 
magnetic resonance (NMR) studies for each TPR domain noted binding, a global loss in 
peak intensity due to line broadening prevented chemical-shift mapping of the S100A1 
binding site on each TPR domain of STIP1.  
4.2 Materials and methods 
4.2.1 Protein purification 
Recombinant STIP1 or individual TPR domains (TPR1 (residues 1-118), TPR2A 
(residues 217-352) and TPR2B (residues 353-480)) were cloned into pDEST17 
expression vectors (Invitrogen-ThermoFisher Scientific). Each construct contained an 
additional N-terminal 6xHis-tag joined by a cleavable tobacco etch virus (TEV) 
recognition site to facilitate tag removal. Individual constructs were transformed into 
Escherichia coli (E. coli) BL21 (DE3) pLysS strain and grown in standard M9 minimal 
media at 37 °C to an OD600 of 0.9. Expression was induced with 1 mM isopropyl β-D-1- 
thiogalactopyranoside (IPTG) and cultures were grown at 22 °C overnight. Protein 
samples for NMR spectroscopy were expressed in standard M9 media supplemented with 
1 g/L 15N-labeled ammonium chloride.  
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Recombinant STIP1 proteins were purified by Ni2+-affinity chromatography using 
Ni Sepharose 6 Fast Flow beads (GE Healthcare Life Sciences). 6xHis-tag cleavage was 
achieved by incubation with 6xHis tagged TEV overnight at 22°C. TEV and 6xHis tag 
were subsequently removed by additional Ni2+-affinity chromatography. 
pETDuet vector encoding S100A1 (kindly provided by Dr. Gary Shaw) was 
transformed into E. coli BL21(DE3)-RIL and cultures were grown in standard M9 
minimal medium or in M9 supplemented with 1g/L 15N-labeled ammonium chloride for 
NMR spectroscopy studies. Cultures were grown to an OD600 of 0.9 and induced with 1 
mM IPTG and grown overnight at 22°C. The bacterial pellet was resuspended in 50 mM 
Tris-HCl, 5mM MgCl2, pH 8.0 and lyzed by French press at 10,000 psi. Cellular debris 
were pelleted by centrifugation at 40,000 x g for 30 minutes. Supernatant was filtered 
through a 0.45 µm syringe filter (Thermo Scientific) and loaded onto a 2 mL HiTrap Q 
anion exchange column (GE Healthcare) equilibrated in Buffer A (25mM Tris-HCl, 1 
mM EDTA, 1 mM DTT, pH 8.0) using a AKTA FPLC (GE Healthcare) at a flow rate 1 
mL/min. The column was washed with 10 column volumes of Buffer A and subsequently 
eluted by a 20-column volume linear gradient of Buffer A with 1 M NaCl. Fractions 
containing S100A1 were pooled and the CaCl2 concentration was adjusted to 5 mM. 
Fractions were incubated with phenyl-Sepharose resin (Amersham Bioscience) for 1 hour 
at room temperature and washed with 25 mM Tris-HCl, 100 mM NaCl, 1 mM DTT, 
1mM CaCl2, pH 8.0. Bound S100A1 was eluted with 25 mM Tris-HCl, 100 mM NaCl, 1 
mM DTT, 5 mM EGTA, pH 8.0 and all proteins were dialyzed into 10 mM HEPES, 
100mM NaCl, 1 mM DTT, pH 8.0 with 5 mM CaCl2 or 5 mM EGTA for further studies.  
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4.2.2 Analytical ultracentrifugation – sedimentation equilibrium  
Analytical ultracentrifugation (AUC) experiments were preformed at 20 °C on 
STIP1 (18 µM) and S100A1 (30 µM), or STIP1 and S100A1 mixtures containing 8 µM 
and 48 µM of each protein, respectively, using a Beckman Optima XL-A Analytical 
Ultracentrifuge equipped with an An-60Ti rotor containing six-channel Epon-charcoal 
centerpieces and 1.2 cm path length (Biomolecular Interactions and Conformations 
Facility, University of Western Ontario). Absorbance measurements were collected at 
250 nm in 0.002 cm radial steps and averaged over 10 scans. Sedimentation equilibrium 
measurements were collected at rotor speeds of 12 000, 15 000 and 18 000 rpm (STIP1) 
or 20 000, 24 000 and 28 000 rpm (S100A1) or 7 000 and 10 000 rpm (STIP1-STIP1 





(Equation 1) where C is the concentration of protein at radius x, C0 is the concentration at 
initial radius x0, ω is the angular velocity, vbar is the partial specific volume of the protein, 
ρ is the solvent density, R is the ideal gas constant, T is the absolute temperature, I0 is the 




4.2.3 Isothermal titration calorimetry (ITC) 
Binding of STIP1 and TPR domains to S100A1 was measured using a 
MicroCal VP-ITC calorimeter or Nano-ITC (TA Instruments) at 25°C. All protein 
concentrations for S100A1 correspond to dimer concentrations. Twenty-five to 30 
aliquots of 5 µL STIP1 (60 µM) or individual TPR domains (~150 µM) were titrated to 
S100A1 (~ 30-70 µM). Buffer blank or ligand into buffer titrations demonstrated 
negligible heats of binding and heats of dilution, respectively. Each titration was 
replicated in duplicate. Isotherms were fit to a single-site binding model using Origin or 
NanoAnalyze software provided by the manufacturer, where Kd is the dissociation 
constant, n is the stoichiometry of binding and ΔH and ΔS represent the change in 
enthalpy and entropy of binding, respectively. 
4.2.4 Nuclear magnetic resonance (NMR) spectroscopy 
Nuclear Magnetic Resonance (NMR) Spectroscopy experiments were preformed 
on a Varian Inova 600 MHz NMR spectrometer equipped with xyz-gradient triple 
resonance cryogenic probe at 25 °C. Backbone resonance assignments for TPR2B (~400 
µM) were obtained from HNCACB and CBCA(CO)NH experiments prepared in 50 mM 
sodium phosphate, 50 mM NaCl, 1 mM DTT, pH 7. Backbone amide resonance 
assignments for TPR1, TPR2A and S100A1 were obtained from the BioMagResBank 
under accession numbers 18691, 18689 and 18231, respectively. NMR spectra were 
processed with NMRPipe and analyzed by NMRViewJ or CARA [22-24]. 1H-15N HSQC 
spectra of 15N-labeled S100A1 (~ 200 µM) were collected in the presence of increasing 
TPR domains (~ 0-200 µM). The reciprocal of the binding experiments were collected 




4.3.1 Multiple S100A1 dimers bind to STIP1 with different affinities 
Previous studies have demonstrated that S100-family of proteins complex with 
STIP1 through its structurally related TPR domains; however, the biochemical details of 
S100 binding to STIP1 to date are poorly understood [16, 25]. We have used isothermal 
titration calorimetry (ITC) to measure the binding affinities and characterize the 
thermodynamic details of the STIP1-S100A1 complex. 
S100A1 bound to full-length STIP1 with high affinity in the presence of Ca2+. No 
heat change was detected upon Ca2+ chelation, suggesting STIP1-S100A1 complex 
formation is Ca2+ dependent (Figure 4.1A and 4.1B). The change in enthalpy (ΔH) upon 
STIP1 titration to S100A1 is highly endothermic indicating complex formation is 
entropically driven and likely involving a large number of hydrophobic contacts (Figure 
1.A). Consistent with this hypothesis, Ca2+ binding to S100-family of proteins results in 
structural rearrangement of the EF-hand α-helical motifs resulting in the exposure of a 
hydrophobic interface involved in numerous S100-family ligand interactions [7]. The 
stoichiometry of binding of STIP1 to S100A1 deviated dramatically from a single-site 
binding model, suggesting multiple S100A1 dimers bind a single molecule of STIP1. 
This agrees with previous studies demonstrating the S100 family members S100A2 and 
S100A6 bind to multiple individual TPR domains (TPR1, TPR2A and TPR2B) of STIP1 
[16]. Interestingly, only a single inflection point is seen in the binding isotherm and it 









Figure 4.1. STIP1 binds multiple S100A1 dimers in a Ca2+-dependent manner. 
Isothermal titration calorimetry thermogram of STIP1 binding to S100A1 in the presence 

















Due to the potential complexity of STIP1 binding to S100A1, measurements were 
conducted on individual TPR (TPR1, TPR2A and TPR2B) domains of STIP1 to obtain 
greater insight into complex formation. Binding affinities between the individual TPR 
domains and S100A1 differed significantly, approximately 15-fold range between the 
strongest and weakest interaction (Figure 4.2A. 4.2B, and 4.2C) (Table 1). Due to the 
relatively weak binding of the TPR2A domain compared to the other TPR domains 
(TPR1, TPR2B), the enthalpy and binding affinity could not be accurately determined for 
this interaction (Kd = ~ 15 µM). TPR2B bound to S100A1 with the highest affinity (Kd = 
0.76 ± 0.01 µM), approximately 6 folds greater than TPR1 (Kd = 4.37 ± 0.1 µM). The 
enthalpies of binding to each TPR domain were endothermic in agreement with the 
values seen for full-length STIP1 and confirm S100A1 complex formation to each TPR 










Table 1. Thermodynamic parameters of TPR domains of STIP1 binding to S100A1. 
TPR domain na Kd (µM)b ΔHb (kcal/mol) TΔSb (kcal/mol) ΔGb (kcal/mol) 
STIP1 0.19 0.59 ± 1.2 72.9 ± 5.8 81.4 -8.5 ± 6.0 
TPR1 0.95 4.37 ± 0.1 55.4 ± 1.0 62.6 -7.2 ± 1.0 
TPR2A - - - - - 
TPR2B 0.96 0.76 ± 0.1 20.8 ± 0.3 29.1 -8.3 ± 0.3 
aBinding stoichiometry of dimeric S100A1 and the TPR domains of STIP1 
bKd is the dissociation constant and ΔH, ΔS and ΔG are the change in enthalpy, entropy 




















Figure 4.2. The TPR domains of STIP1 bind a single S100A1 dimer with various affinities. 




4.3.2 STIP1 binds to three S100A1 dimers 
Studies have indicated additional S100 proteins complex with STIP1 through 
TPR-motif interactions in each domain through pulldown experiments [16]. These 
include S100A2 and S100A6, but not S100B, S100A4, S100A10, S100A11, S100A12 or 
S100A13 [13]. Thus, this is not a property shared by all S100 family members. The S100 
proteins identified to bind STIP1 differed in the number of S100 dimers that bind a single 
molecule of STIP1. Our ITC results did not fit perfectly to a single-site model, thus we 
could not say for certain the stoichiometry of binding of S100A1 to STIP1. Thus, AUC 
experiments were conducted to gain additional insights into the stoichiometry of binding 
of S100A1 to full-length STIP1. S100A1 exhibited a Mobs value of 24.2 ± 0.2 kDa, 
consistent with previous studies suggesting S100A1 exists as a homodimer in solution of 
a calculated molecular weight of 21.1 kDa based on the amino acid sequence (Figure 
4.3A). Alternatively, STIP1 presented a Mobs value of 55.3 ± 0.9 kDa, reasonably close to 
the predicted molecular weight of 62.6 kDa and consistent with current monomeric 
models of STIP1 function in solution during Hsp70 and Hsp90 client protein transfer 
(Figure 4.4B). AUC of STIP1 at saturating concentrations of S100A1 revealed the 
formation of a larger molecular weight species with a Mobs of 126.1 ± 1.2 kDa (Figure 
4.4C). These results are in agreement with a single S100A1 dimer binding to each of the 





Figure 4.3. A single STIP1 molecule binds three S100A1 dimers simultaneously. 
Sedimentation equilibrium of AUC (A) S100A1 obtained at rotor speeds 20 000, 24 000 and 28 000 rpm (black, blue and red, 
respectively), (B) STIP1 measured at 12 000, 15 000 and 18 000 rpm (black, red, blue, respectively) or(C) STIP1-S100A1 complex 




4.3.3 S100A1 shares a common interface when binding each TPR 
domain 
The disparity in affinities and significant differences in thermodynamic properties 
of S100A1-TPR interactions suggests there are differences in the binding interfaces 
between these interactions. Thus, we used nuclear magnetic resonance (NMR) 
spectroscopy to define residues involved in complex formation at the molecular level. 
Titration of 15N-isotopically labeled S100A1 with increasing concentrations of each TPR 
domain (TPR1, TPR2A and TPR2B) resulted in a systematic global reduction in peak 
intensity (Figure 4.4). The loss in signal is likely the result of line broadening through 
enhanced relaxation, the consequence of increased molecular weight of the S100A1-TPR 
complex (37.4 kDa) in relation to the unbound S100A1 spectrum (21.1 kDa). 
Interestingly, a significantly greater loss in peak intensity was observed in residues 
localized to a continuous region spanning α-helices III and IV of S100A1 (Figure 4.4A, 
B and C). Residues of S100A1 showing the largest peak intensity attenuations upon 
addition of each TPR domain were mapped to an identical region suggesting that they 







Figure 4.4. TPR domains of STIP1 share a common binding interface on S100A1. 
Graphical representations of chemical shift changes observed in 1H-15N spectra of 15N-lablled S100A1 in the presence of (A) TPR1, 
(B) TPR2A or (C) TPR2B (left)(red line: average decrease in signal intensity upon TPR titration; black line: one standard deviation 
from the mean decrease in signal intensity) Chemical shift changes mapped on to S100A1 structure (PDB:2LP3)[33] (right). Regions 
of S100A1 that demonstrated a greater than one standard deviation from the mean average decrease in signal intensity are colored in 
red.   
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The similarity of the S100A1-TPR binding regions suggests differences in affinity 
and thermodynamics are likely due to differences in amino acid composition on the 
individual TPR domains. To determine the regions of each TPR domain involved in 
S100A1 complex formation, the reciprocal experiment was conducted where 15N-labeled 
TPR domains were titrated with S100A1. A global decrease in signal intensity was 
observed for each TPR spectrum consistent with the results obtained in the S100A1 
spectra (Figure 4.5A, B and C). Unfortunately, no significant localized deviation from the 
global decrease in signal intensity was observed for each TPR titration. This result 
prevented accurate mapping of the S100A1 binding site on each TPR domain. Further 
study is required to identify the S100A1 binding site in each TPR domain of STIP1 by 






Figure 4.5. Graphical representations of chemical shift changes observed in 1H-15N spectra of 15N-labelled (A)TPR1, (B) 
TPR2A or (C) TPR2B in the presence of S100A1. 





The studies presented here provide molecular details of the interactions between 
S100A1 and STIP1. ITC thermograms indicated a high affinity interaction between 
S100A1 and full-length STIP1. The stoichiometry of binding (n) differed dramatically 
from a single one-site model; however, only a single inflection point was evident in the 
thermograms, suggesting multiple binding sites with similar thermodynamic properties. 
The possibility of multiple binding sites complicated fitting the isotherm to a single 
binding model, thus we investigated binding to individual TPR domains. Previous studies 
have demonstrated that each individual TPR domain of STIP1 is capable of binding 
related S100 family members (S100A2 and S100A6) [16]. However, these studies were 
limited to affinity pull down experiments and the thermodynamic details of S100 binding 
to each TPR domain and S100 proteins were lacking. Though similar in structure, 
S100A2 and S100A6 dimers have been shown to bind STIP1 at stoichiometric ratios of 
4:1 and 2:1 by pull-down experiments, respectively [16]. Steric hindrance or 
conformational rearrangements in STIP1’s modular structure may alter the binding 
capacity of STIP1 for S100 proteins, even though individually each TPR domain 
possesses the capacity to bind S100 proteins. 
ITC binding experiments of each TPR domain titrated to S100A1 revealed 
significantly different binding properties. Binding affinities differed approximately 20 
fold between the tightest bindings TPR2B (Kd = 0.8 µM) and weakest, TPR2A (Kd 
estimated to be ~ 15 µM). While representative of TPR affinities to S100A1, we cannot 
rule out potential cooperatively in binding in the context of the full-length protein. TPR 
domains are believed to function as ancient protein-protein interaction modules and are 
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often seen in tandem across multiple TPR containing proteins [26]. It is therefore not 
uncommon for a single ligand to interface with multiple TPR domains, as is seen with the 
prototypical and best characterized STIP1 binding partners, Hsp70 and Hsp90 [21, 27, 
28]. Interestingly, in the case of Hsp70 and Hsp90 coordination, while each TPR domain 
is capable of recognizing C-terminal region ‘EEVD” motifs of Hsp70 and Hsp90, the 
individual TPR domains take on different roles to regulate binding properties of the full-
length molecule [18]. TPR1 and TPR2B show preference for Hsp70 binding, while 
Hsp90 interacts with TPR2A-TPR2B. In addition, it appears that Hsp70 and Hsp90 are 
not capable of binding each TPR domain concurrently due to steric hindrance or 
conformational changes in full-length STIP1. The binding model for S100A1 differs in 
that each TPR domain is occupied by an S100A1 dimer.  
Sedimentation equilibrium AUC experiments confirmed the dimeric and monomeric 
native states of S100A1 and STIP1, respectively. There has been some disagreement as to 
the native state of STIP1 in solution as studies have suggested monomeric and dimeric 
forms [21, 29-31]. The most detailed and recent model of STIP1 suggests a large 
elongated structure in the free state and attributing previous dimeric models as the result 
of an atypical elongated structure and large hydrodynamic radius of the full-length 
protein [29, 32]. 
To date numerous TPR interactions have been described between S100A1 and 
additional S100 family members. Coincidentally, a large number of the TPR-motif 
interactions identified thus far segregate into additional co-chaperones and members of 
the heat shock protein complex, such as FKBP52, Cyp40, PP5, CHIP [15, 25]. These co-
chaperones utilize TPR motifs to associate with Hsp70 and Hsp90 influencing many 
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cellular processes. Thus, these studies implicate S100A1 and additional S100 proteins in 
a regulatory network of heat shock protein machinery in protein client refolding. 
S100 interactions with chaperone and co-chaperone proteins vary on their dependence 
on Ca2+ for protein binding, suggesting differing modes of interaction, though structural 
details involving these interactions are scarce. Therefore, we used NMR chemical shift 
perturbation mapping to determine the binding interfaces between S100A1 and the 
individual TPR domains (TPR1, TPR2A and TPR2B) of STIP1. Titrations of 15N-labeled 
S100A1 with each TPR domain lead to a systematic decrease in signal intensity. 
Chemical shift mapping revealed a significant decrease in intensity for residues localized 
to α-helices III and IV of EF-hand motifs. Each S100A1 subunit is composed of a 14-
residue N and 12-residue C-terminal calcium-binding loop [33]. The latter is situated 
between helices III and IV. NMR solution structures of the apo- and Ca2+ bound forms 
indicate Ca2+ binding triggers a large conformational change resulting in the reorientation 
of α-helix III by approximately 100° and exposing a large hydrophobic region in α-helix 
IV[5]. The Ca2+-dependant binding of STIP1 presented by ITC and the significant NMR 
peak intensity changes in α-helix IV upon TPR binding agrees with the interaction 
localizing to an interface spanning α-helix IV and provides rationale for the interaction 
being Ca2+ dependant. The mapped hydrophobic interface on S100A1 for TPR binding is 
consistent with a variety of S100-family member ligands that associate in a Ca2+-
dependant manner [4]. Interestingly, the stoichiometry of complex formation determined 
by ITC and AUC suggest a single TPR domain binds a single S100A1 homodimer. This 
differs from many S100-target peptide complexes solved to date which display 
symmetric binding [34-36]. However; these studies involved short peptides 
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corresponding to ligand binding regions, which may not be representative of full-length 
proteins, where alternate structural elements may occlude binding to both S100 
monomers. 
While NMR spectra of each TPR domain did show a global peak intensity change 
upon S100A1 titration, the binding interface could not be mapped to a particular region. 
The local effects of binding may be masked due to intermediate exchange rates or the 
large size of the complex. However, comments on particular regions of the TPR domains 
that may potentially be involved in binding to S100A1 can be made using the structural 
information available. Crystal structures of the TPR1 and TPR2A domains reveal a 
hydrophobic cradle shaped groove extending on one side of each TPR domain [18]. This 
site serves as the binding interface of the disordered C-terminal ‘EEVD’ motifs of Hsp70 
and Hsp90, respectively, and is the canonical binding site for other TPR-motif ligands. 
However, due to the concave nature of the mapped S100A1 binding interface and this 
canonical TPR binding site, it is unlikely the binding site of S100A1. Steric clashing 
generated by α-helices III of S100A1 subunits and the N and C terminal α-helices of 
each TPR domain would likely prevent binding to α-helices IV of S100A1 unless 
significant conformational deviations occur in the bound state of the complex. As well, 
the similarity of the binding site on S100A1 for each TPR domain suggests that 
differences in binding and thermodynamic properties in the interactions is likely due to 
the amino acid compositions and residue contacts formed by each TPR domain on the 
shared S100A1 binding site. Further, study of the TPR domain-binding site for S100A1 is 
needed to identify regions involved in complex formation. 
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The S100 families of binding proteins have been shown to demonstrate unique and 
characteristic expression profiles in multiple human diseases including different forms of 
cancer and neurodegenerative disorders such as ALS and AD [6, 7, 12]. Multiple 
interactions have been documented between S100A1 and other S100-famliy members 
with TPR containing proteins, with a large number S100A1 ligands identified to be 
involved in the Hsp complex machinery, though the molecular details of these 
interactions has not previously been described. Our studies describe the molecular details 
of STIP1 interaction with S100A1 and its TPR domains, which may influence STIP1 
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Stress-inducible phosphoprotein 1 (STIP1) has been extensively studied as a 
cochaperone of the Hsp70/Hsp90 protein client folding machinery [1-4]. STIP1 couples 
transfer of immature or abnormally folded proteins from Hsp70 to Hsp90 during the 
client folding cycle [5]. It is now accepted that extracellular STIP1 can function as a 
potent neuroprotective and neuroproliferative signaling molecule through complex 
formation with the cellular prion protein (PrPC) [6-10]. The resultant signaling cascade 
rescues neurons from various cellular stressors including staurosporine-induced 
programmed cell death and ischemia [6, 11]. This neuroprotection has recently been 
extended to Aβ oligomer (AβO) toxicity, suggesting STIP1 signaling as an endogenous 
protective mechanism in Alzheimer’s disease (AD) [12]. In addition, recent studies have 
identified particular members of the S100- family of Ca2+ sensors as STIP1 ligands [13]. 
S100 proteins altered expression has been implicated in several diseases including 
cardiomyopathy, cancer and AD [14].  
Detailed structural studies have been conducted to dissect STIP1 co-chaperone 
interactions with Hsp machinery [1-3, 15]. In contrast, few details are available 
concerning STIP1 interaction with PrPC and the S100-famliy of proteins [13, 16]. The 
work presented in this thesis addressed the molecular details of STIP1 interactions with 
PrPC and S100A1 proteins in order to provide a better understanding of alternate STIP1 





5.1 Structural characterization of STIP1 domains 
The majority of NMR studies to date involving STIP1 have focused on the yeast 
homologue [2, 3, 15]. Where as complementary x-ray crystallographic data and other 
biophysical techniques suggest a conserved structure, the sequence identity between 
mouse and yeast STIP1 is approximately 40% [1]. Thus, we characterized mouse STIP1 
by NMR to facilitate future ligand studies. We confirmed the less than expected number 
of observable STIP1 NMR amide resonances was not due to dimer formation of STIP1 or 
the TPR2A domain, confirming a monomeric model of STPI1 in solution, which has 
been challenged in previous studies [17, 18]. Rather, the lack of amide resonance signals 
is likely reflective of STIP1’s large molecular weight (62.6 kDa) and predicted elongated 
tertiary structure [15, 16].  Therefore, we assigned the amide proton resonances of the 
structured domains of STIP1 (TPR1, TPR2A, TPR2B and DP2). Only a partial 
assignment of DP1 could be obtained due to low signal strength (chapter 2).  
The amide backbone resonance assignments lay the foundation for determining the 
molecular details of PrPC (chapter 3) and S100A1 (chapter 4) complexes. These studies 
can be extended to other STIP1 ligands, such as inhibitors of Hsp90 complex formation 
with STIP1.  Hsp90 client proteins include numerous oncogenic kinases, receptors and 
transcription factors including Her2/neu, Bcr-Abl, vascular endothelial growth factor 
(VEGF) and Raf-1 [19]. Inhibition of Hsp90 results in rapid proteasomal degradation of 
these targets. Traditional Hsp90 inhibitors target the ATPase activity of Hsp90, which 
have the undesired effect of Hsp70 induction resulting in resistance to apoptosis [20]. An 
alternate approach has been proposed by Regan and co-workers, which targeted STIP1-
Hsp90 complexes, thus indirectly interrupting stabilization of oncogenic targets [21]. 
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Importantly, these small molecules demonstrated anti-tumorogenic effects without 
inducing Hsp70 overexpression suggesting they may escape the positive feedback 
mechanism of Hsp70 induction inherent to traditional Hsp90 ATPase inhibitors [22].  
5.2 Mapping of AβO interface on PrP 
PrPC is a high affinity receptor for AβO whose complex induces synaptic 
dysfunction, inhibition of long term potentiation (LTP), loss of dendritic spines and, 
ultimately, neuronal cell death [12, 23, 24]. AβO binding to PrPC is thought to be 
mediated by two distinct regions in the disordered N-terminal of PrPC. These include a 
highly basic cluster ‘KKRPK’ spanning residues 23-27 and residues 95-110 of PrPC [23, 
25]. Our NMR studies of 15N-labelled PrP (90-231) titrated with preformed AβOs 
revealed a short, highly localized region involved in AβO binding spanning residues 90-
110 of PrP. These results are consistent with the literature that implicates residues 95-110 
in AβO binding [23, 25]. In addition, we noted small but notable chemical shift changes 
of C-terminal residues of the globular domain of PrP. These may arise due to 
conformational changes in PrP upon AβO or from transient contacts between PrP or AβO 
species. No chemical shift changes or changes in peak intensity were noted for the N-
terminal residues of PrP (23-95). High sequence redundancy and peak overlap prevented 
the assignment of residues 23-95. Thus, we cannot rule out the possibility of minor, but 
localized chemical shift changes in residues 23-95 upon AβO titration. However, 
antibodies directed against residues 90-110 of PrP were sufficient to block AβO binding 
to PrP, inhibit AβO neurotoxicity and improved cognitive deficits in AD transgenic 
mouse models [24, 26, 27]. Thus, targeting residues of PrP 90-110 appears sufficient to 
disrupt AβO induced deficits and may be a viable therapeutic approach in AD. 
  
138 
5.3 Domains of STIP1 participating in PrP binding 
The interaction between STIP1 with PrPC has been well documented to elicit 
neuroprotective signaling in response to cellular stressors [6, 7, 11, 12]. Complex 
formation has been suggested to be mediated between the TPR2A domain of STIP1 and 
the disordered N-terminal of PrPC [6]. In the present study, we confirmed a high affinity 
(1 x10-7 M Kd) complex between STIP1 and PrPC, while demonstrating that additional 
domains of STPI1 are involved in binding. The structurally related TPR1 and TPR2A 
domains, but not TPR2B, bound PrP. TPR1 and TPR2A binding were mutually 
exclusive; suggesting binding of either domain to PrPC occludes the binding site of the 
other. In addition, the DP1 domain was found to interact with the N-terminal (residues 
23-95) of PrPC. This is the first reported instance of a binding partner for the DP1 domain 
of STIP1.  
The involvement of multiple domains of STIP1 in ligand binding is reminiscent of 
STIP1 cochaperone interactions. Hsp70 binding to STIP1 is shared between the TPR1 
and TPR2B domains and has functional consequences in for the proposed mechanism of 
Hsp client transfer [3]. Upon Hsp90 recruitment, the high affinity Hsp70 site shifts from 
TPR1 to TPR2B to presumably to spatially orient the client protein for efficient transfer 
to Hsp90 at the TPR2A site [3]. Due to the modular structure of STIP1 and structural 
homology of individual TPR domains, multi-domain STIP1 ligand interactions may be a 





5.4 Domains of STIP1 that inhibit PrP-AβO toxicity 
We have previously demonstrated ectopic STIP1 treatment is capable of efficiently 
inhibit Aβ oligomer toxicity in a PrPC dependent manner [12]. The identification of novel 
domains participating in PrP complex formation led us to investigate the regions of 
STIP1 responsible for its neuroprotection from AβO insult. Surface plasmon resonance 
(SPR) was utilized to assess AβO binding to PrP (23-231) and the influence of STIP1 and 
its individual domains in vitro. Our findings indicated that TPR1 and TPR2A domain of 
STIP1, but not DP1, could inhibit AβO binding in a concentration dependant manner.  
While DP1 may not directly participate in STPI1 inhibition of AβO binding, it likely 
contributes to the greater binding affinity of STIP1 for PrP compared to the individual 
domains alone. Considering TPR1 and TPR2A bind residues 90-231 of PrP, they may 
physically occlude or induce conformational changes in PrP that inhibit AβO binding. 
STIP1 binding to PrP has been suggested to induce significant conformational changes in 
PrP [16]. Importantly, inhibition of AβO binding to PrP by TPR1 and TPR2A translated 
to primary mouse hippocamapal neurons and rescued them from AβO induced cell death.  
STIP1-PrPC induces Ca2+ influx resulting in downstream neuroprotective signaling 
events through the alpha 7 nicotinic acetylcholine receptor (α7nAchR) [10]. Therefore, 
we cannot rule out that TPR1 and TPR2A inhibition of AβO neuronal cell death is not 
due to activation of a neuroprotective signaling cascade. Indeed, genetic deletion of 
α7nAChR resulted in enhanced memory deficits and AβO accumulation in young 5-
month old APP transgenic mice [28]. Alternatively, STIP1 induced neuroprotective 
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signaling events and direct inhibition of AβO binding to PrPC may act in concert to 
protect primary hippocampal neurons against AβO neurotoxicity.  
STIP1 upregulation has been noted in APPswe/PS1dE9 mouse model of AD and in 
AD-afflicted brain homogenates [12]. Additionally, decreased levels of STIP1 in 
mammalian neurons or knockdown of STIP1 in C. elegans increases the toxicity of 
amyloid peptides [29][12]. Thus, extracellular STIP1 may serve as an endogenous 
protective mechanism against neurotoxic AβOs in early stages of AD. 
5.5 Regions of TPR1 and TPR2A involved in PrP 
binding 
While previous studies have suggested residues 230-245 of STIP1 and 113-128 of 
PrP are involved in complex formation, molecular details at the residue level were absent 
[6, 16]. The high structural similarity of TPR1 and TPR2A and their competitive binding 
to PrP led us to investigate if complementary interfaces on each domain are involved. 
Similar interfaces have been described for TPR1 and TPR2A binding to the C-terminal of 
Hsp70 and Hsp90, respectively, as they both utilize conserved carboxylate clamp 
residues to coordinate the acidic Hsp C-terminal tail [1]. Interestingly, NMR studies 
revealed TPR1 and TPR2A binding interfaces for PrP are significantly different. TPR1 
residues spanning the C-terminal of α-helix 6 and the interconnecting loop region 
connecting it to α-helix 7 showed significant chemical shift changes. In contrast, the 
TPR2A binding interface extended diagonally across the concave TPR2A surface which 
overlaps with the Hsp90 binding site [1]. 
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Hsp90 chaperone function is critical for assuring proper folding of client proteins, 
solubilizing protein aggregates or facilitating their targeting for proteasomal degradation 
[19]. Hsp70 and Hsp90 have been shown to block Aβ1-42 aggregation in vitro [30]. Hsp90 
and other Hsps also promote Aβ clearance by the stimulation of phagocytosis in 
microglia [32]. Thus, modulation of Hsp proteins has gained traction as a possible 
therapeutic pathway in AD [33]. 
Given both Hsp90 and STIP1 are secreted through an exosomal non-canonical 
pathway and the TPR2A domain is involved in both PrP and Hsp90 binding, we 
investigated the influence of PrP on Hsp90 binding to STIP1 [34, 35]. Interestingly, PrP-
STIP1 complex formation promoted Hsp90 binding, suggesting they form a ternary 
complex at the cellular membrane. STIP1 binding may induce structural conformational 
changes in PrP, which may in turn recruit Hsp90 [16]. Hsp90 has been localized to the 
cellular membrane, thus PrP-STIP1-Hsp90 complexes may form on the cellular surface 
and influence STIP1 signaling events [36]. 
5.6 Molecular details of STIP1 interaction with S100A1 
S100A1 is a Ca2+-binding protein sensor that modulates protein-protein interactions in 
the cell [14]. S100A1 along with S100B and S100A6 are overexpressed in AD and are 
considered as disease biomarkers [37]. S100A1 has been found to interact with various 
co-chaperones through TPR domain interactions [13, 38]. TPR domains are common 
structural elements shared by many Hsp70 and Hsp90 co-chaperones as they coordinate 
binding to the highly conserved C-terminal Hsp ‘EEVD’ motifs [39]. Thus, S100A1 and 
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other S100 family members may function as regulators of Hsp client refolding by 
influencing which co-chaperones are involved.  
We have shown that S100A1 dimer bound each of the single TPR domains of STIP1 
with various affinities in a Ca2+-dependent manner. Interestingly, this differs from many 
S100A1 binding partners, which bind symmetrically to each S100 monomer, although 
asymmetric interactions have been described for other S100 family members [40, 41]. 
However; it is important to note many studies displaying symmetrical binding utilize 
short peptide sequences. In the full-length proteins, additional structural elements of the 
S100 ligand may occlude the binding pocket of the S100 proteins, preventing symmetric 
binding to each S100 monomer.   
Our NMR studies indicated each TPR domain (TPR1, TPR2A and TPR2B) bound 
identical hydrophobic region composed of α-helices III of each S100 monomer. This 
observation agrees with these interactions being Ca2+-dependant. In the absence of Ca2+, 
this region is inaccessible as it blocked by helix IV of each S100A1 subunit [42]. Upon 
Ca2+ binding, helices IV of each S100 monomer undergo a large conformational change 
by rotating approximately 100° and exposing the hydrophobic interface.  
Unfortunately, the S100A1 binding interface on each TPR could not be determined 
due to line broadening likely due to the large molecular weight or intermediate exchange 
rates of the complex. However, due to the concave nature of the S100A1 binding site and 
each TPR domain, binding likely involves the N or C-terminal helices of each TPR 
domain to minimize steric clashing [1, 42]. Further study is required to determine TPR 
site for S100A1 binding.   
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S100A1 and STPI1 are both found in the cytoplasm as well as the extracellular space 
[34, 43]. S100A1 may modulate STIP1 ligand interactions influencing critical cellular 
processes such as protein folding or cell signaling events through Hsp proteins or PrPC, 
respectively. Thus, S100A1 over-expression in AD may alter the processing of Aβ and 
tau aggregates by STIP1 or regulate formation of neuroprotective complexes through 
PrPC.  
5.7 Future directions 
Our results suggest a ternary complex may form between STIP1, PrP and Hsp90; 
however, the details of the regions of PrP involved and the stoichiometry of the 
interaction are unknown. Different length PrP constructs can be used to determine if 
Hsp90 recognizes the globular C-terminal or N-terminal of PrP. The solid support assay 
developed here can be used with PrP (90-231) to rule out Hsp90 binding to the N-
terminal of PrP. As well, sedimentation equilibrium or gel filtration experiments of 
STIP1-PrP-Hsp90 can be preformed to determine the stoichiometry of the complex, as 
larger species will change the elution profile or the rate the protein sediments. 
Our results suggest the formation of a STIP1-Hsp90-PrP ternary complex in vitro, 
however; it is unclear if the complex occurs on the cell surface or its effect on STIP1 
signaling. Endogenously expressed GPI-anchored PrPC may behave differently than when 
immobilized on to the polystyrene surface used in our solid support assays. 
Immunohistochemistry and confocal microscopy studies may reveal if the proteins 
colocalize on the cellular surface or if they are internalized together in intracellular 
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compartments. Co-immunoprecipitaton of isolated membrane fractions may also reveal if 
ternary complexes occur in cell culture.   
The significant global loss in signal intensity prevented the determination of the 
S100A1 binding interface on the individual TPR domains of STIP1. This is potentially 
due to the increased size of the complex in relation to the individual proteins alone. A 
common strategy for signal enhancement involves deuteration of the protein samples. 
Due to their large size, larger proteins experience slower tumbling and thus enhanced 
relaxation and decay resulting in loss of signal. Deuteration removes most 1H protons 
improving relaxation rates thus resulting in a greater signal strength and resolution.  
Alternatively, cross-saturation experiments can be used to identify the TPR binding 
interface and have been used for protein-protein complexes >50 kDa. This technique 
relies on uniformly labeling the target protein for which the interface is to be determined 
with 2H and 15N (TPR domain). The aliphatic proton resonances of the unlableled binding 
partner (S100A1) is non-selectively irradiated and transferred to the target through cross 
relaxation by protons located at the interface. Thus, only residues at the interface are 
affected and can be identified.  
5.8 Conclusions 
The work presented provides novel molecular details regarding STIP1 complexes 
implicated in AD. STIP1’s modular structure and inter-domain homology, implicate 
extensive multi-domain interactions in PrP and S100A1 binding. Additional domain 
interactions were found to influence STIP1 binding to PrP and influence PrPC dependant 
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AβO neurotoxicity. As well, structural studies of STIP1-S100A1 provided molecular 
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